Cell growth method and pharmaceutical preparation for tissue repair and regeneration

ABSTRACT

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a Divisional of U.S. application Ser. No.12/677,610, which is the U.S. National Stage of PCT/JP2008/002503, filedSep. 10, 2008, which claims priority from Japanese Application Nos. JP2007-235436, filed Sep. 11, 2007, JP 2007-236499, filed Sep. 12, 2007,JP 2007-267211, filed Oct. 12, 2007, JP 2007-278083, filed Oct. 25,2007, and JP 2007-278049, filed Oct. 25, 2007, the entire disclosures ofwhich are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to: a method for growing, rapidly andmassively ex vivo, cells collected from a living subject; cells grown bythe method; a pharmaceutical preparation for biological tissue repairand regeneration comprising the cells; and a method for producing thepharmaceutical preparation. This method is suitable particularly forautotransplantation of mesenchymal stem cells and is applicableparticularly to repair and regeneration of a tissue of the nervoussystem.

BACKGROUND ART

Heretofore, recovery in the functions of injured nervous tissues hasbeen considered to be very difficult.

However, neural stem cells that retain the ability to grow autonomouslyand pluripotency have been found in the adult brain in recent years.Based on this finding, regenerative medicine has been studiedenergetically on the central nervous system as well. Cell therapy forreplenishing injured cells has been thought to be closest to practicaluse as the regenerative medicine using stem cells. In the cell therapy,cells provided by a donor (hereinafter, referred to as donor cells) arecultured, grown, and/or induced to differentiate ex vivo. The cells inan appropriate form are administered into a living subject as arecipient to replenish the injured tissue cells of the recipient.

For brain neurological disease, an attempt has been made on ischemia ortrauma models, in which cells having differentiation potency into cellsof the nervous system are extracted from tissues, then cultured, andtransplanted to an individual. For example, the present inventors havealready found that a cell fraction containing cells capable ofdifferentiating into neuron cells is present in bone marrow cells andfurther demonstrated that transplantation of these cells to ratdemyelinated spinal cord models remyelinates the demyelinated axons(Patent Document 1).

For using donor cells in the treatment of disease, particularly, in thetreatment of disease having symptoms in the acute phase, such asischemic brain disease attributed to cerebral infarction, it isimportant to grow the donor cells rapidly and massively. Variousattempts to grow cells ex vivo have been made for improving a cellsurvival rate and enhancing a growth rate.

For example, media supplemented with various growth-promoting substancesare used for improving a cell growth rate. For example, Patent Document2 discloses that leukocyte inhibitory factors increase a cell growthrate. Patent Document 3 discloses a medium containing recombinant humanserum albumin for growing hematopoietic cells. Patent Document 4diseases a method for culturing mesenchymal stem cells in a mediumcontaining vitamin C and a basic fibroblast cell growth factor. Use ofother growth factors (e.g., epithelial cell growth factors, nervous cellgrowth factors, liver cell growth factors, thrombopoietin, andinterleukin) is also known in the art.

Culture substrates that more highly enhance a cell growth rate have alsobeen developed. For example, Patent Document 5 discloses a method forculturing mesenchymal stem cells on basement membrane extracellularmatrix.

Moreover, serum is also generally used as a growth-promoting substance.Heretofore, a medium supplemented with approximately 10% to 20% foreignanimal serum including fetal bovine serum (FBS) or other cell growthfactors has been used widely in stem cell culture. However, the animalcells such as FBS differ in composition from lot to lot and also havethe problem of possible contamination with pathogens such as virus orprion.

To cope with such problems, serum-free media have also been developed(see e.g., Patent Documents 2 and 3). However, culture in such aserum-free medium hardly produces growth equivalent to that in aserum-supplemented medium under the present circumstances.

On the other hand, in an attempt to use human serum, human adult serumis used because use of fetal serum is difficult from the ethicalstandpoint (see e.g., Patent Documents 6 to 8). The advantage of use ofthe adult serum is that autoserum of an individual from which the donorcells are collected can be used. The use of the autoserum is verypreferable from the viewpoint of compatibility and safety.

The disadvantage of use of the adult serum is lower growth-promotingactivity than that obtained using, for example, FBS. The adult serumexhibits insufficient cell growth-promoting activity by itself andtherefore, inevitably requires further adding FBS (Patent Document 6) oradding other growth factors (Patent Document 7) for obtaining growthequivalent to that obtained using FBS. However, even when effectsequivalent to those obtained using FBS are obtained by the addition ofgrowth factors or the like, rapid and massive growth cannot be obtainedwhich is applicable to the treatment of disease in the acute phase asdescribed above.

On the other hand, conventional methods for culturing/growing cellscollected from a living subject comprise adding heparin duringcollection of tissues or cells containing blood components from a donorto avoid blood coagulation (see e.g., Patent Document 9 and Non-PatentDocuments 1 and 2). In a typical case (e.g., collection of bone marrowcells for usual bone marrow transplantation), the amount of heparinadministered is approximately tens of U/mL (approximately 20 to 40 U/mL)with respect to the volume of the cell solution. For example, PatentDocument 8 discloses addition, to a bone marrow fluid, of aheparin/buffer solution containing heparin in the range of approximately5 to 15 U/mL. Patent Document 2 discloses a method, wherein heparin isfurther contained in a culture medium.

Heparin is also used as a growth aid, in addition to the application toprevent blood coagulation as described above. For example, PatentDocument 4 discloses that heparin has the effect of enhancing theaffinity of a basic fibroblast growth factor (bFGF) for its receptor.Moreover, Patent Document 10 discloses a modified form of sulfatedglycosaminoglycan containing heparin, as an aid for neural stem cellgrowth. However, even these methods using heparin cannot yet achieve asufficiently rapid and massive growth rate under the presentcircumstances.

Meanwhile, living subjects, when injured, have a mechanism where theinjury site is autonomously repaired. Thus, a certain degree of injurycan be repaired without leaving functional damage. However, theendogenous repair mechanism is not sufficient for a large degree ofinjury. In this case, recovery may be delayed, or the injury may berepaired incompletely, leaving functional damage. Biological tissues,particularly, nervous tissues or the like, receiving such injury haveconventionally been thought to be very difficult to repair. However,with the recent finding of stem cells having pluripotency, an attempthas been made to replenish injured cells with such stem cells. Forexample, Patent Document 11 discloses that mesenchymal stem cells wereadministered to cerebral infarction model rats in the acute phase of thedisease (after 3 to 24 hours of induction of ischemia) and consequentlyproduced significant therapeutic effects.

However, an approach remains to be reported, which is effective forrecovering lost functions in the subacute phase or later where theinjury site is stabilized to some extent due to the passage of time frominjury.

Patent Document 1: Pamphlet of WO02/00849A1 Patent Document 2: NationalPublication of International Patent Application No. 2002-518990 PatentDocument 3: Japanese Patent Laid-Open No. 2005-204539 Patent Document 4:Japanese Patent Laid-Open No. 2006-136281 Patent Document 5: JapanesePatent Laid-Open No. 2003-52360 Patent Document 6: Japanese PatentLaid-Open No. 10-179148 Patent Document 7: Japanese Patent Laid-Open No.2003-235548 Patent Document 8: Japanese Patent Laid-Open No. 2006-55106Patent Document 9: Pamphlet of WO01/48147A1 Patent Document 10: JapanesePatent Laid-Open No. 2005-218308 Patent Document 11: Pamphlet ofWO2005/007176

Non-Patent Document 1: F. Takaku, “Manual of Bone MarrowTransplantation”, first edition, CHUGAI-IGAKUSHA, 1996, p. 86Non-Patent Document 2: Y. Miura, ed., “Method of Hematopoietic Stem CellCulture” first impression of revised 2nd edition, CHUGAI-IGAKUSHA, 1989,p. 38

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

Thus, an object of the present invention is to solve the problems ofconventional techniques in growing cells ex vivo for celltransplantation and to grow cells rapidly and massively at a highergrowth rate than that of conventional methods. A further object of thepresent invention is to provide a highly practical preparation forassisting in tissue repair, using the grown cells. This preparation hastherapeutic effects even when administered in the subacute phase orlater of injury.

Means for Solving the Problems

To attain the object, the present inventors have examined variousconditions and procedures for cell culture and, in the process, haveconducted studies by focusing on heparin usually used for the purpose ofpreventing blood coagulation. Consequently, the present inventors havefound that heparin has significant inhibitory effects on cell growth. Asa result of further studies, the present inventors have found that aslong as cells are cultured under conditions that do not involve contactwith heparin, cells having excellent growth efficiency (growing quickly)can be obtained even in a culture method using allogeneic (includingautogenic) serum instead of FBS, and that the obtained cells are safewith high differentiation potency. Based on these findings, the presentinvention has been completed.

Specifically, the present invention relates to a method for growingcells in a sample collected from a living subject by culturing the cellsin a medium, the method comprising culturing the cells, withoutsubstantial contact with an anticoagulant, in a medium containingallogeneic serum. In this context, it is preferred that the allogeneicserum should have been determined to be negative for a tumor markerand/or an infectious factors. Moreover, it is preferred that theallogeneic serum should be autoserum the subject from which the cellsare collected.

In this context, examples of the serum tumor marker can includeferritin, CEA, AFP, BFP, CA125, CA15-3, CA19-9, CA72-4, STN, DUPAN-2,SLX, ST-439, SPAN-1, SCC, PSA, G- seminoprotein, TPA, CYFRA, PAP, NSE,C-peptide, PIVKA, Pro-GRP, HCGβ, elastase, β2 microglobulin, S-NTX, ananti-p53 antibody, and HER2. Examples of the infectious factors caninclude HIV, ATL, HB, HC, syphilis, and human parvovirus B19.

Moreover, the present invention relates to the method, wherein theamount of the anticoagulant added to the collected sample is less than 5U/mL with respect to the volume of the sample.

Furthermore, the present invention relates to the method, wherein theamount of the anticoagulant in the medium at the start of culture isless than 0.5 U/mL.

Moreover, the present invention relates to the cell growth method,wherein the anticoagulant is heparin, a heparin derivative, or a saltthereof.

The present invention relates to the method, wherein the cells are grownin a medium containing serum.

Moreover, the present invention relates to the method, wherein the cellsare grown in a medium containing serum of an animal individual of thesame species as that of an animal from which the cells are derived.

Furthermore, the present invention relates to the method, wherein thecells are grown in a medium containing autoserum.

The present invention also relates to the method, wherein the medium hasa serum content of 1 to 20% by volume.

The present invention relates to the method, wherein stem cells aregrown.

Moreover, the present invention relates to the method, whereinmesenchymal stem cells are grown.

Furthermore, the present invention relates to the method, wherein humancells are grown.

The present invention relates to the method, wherein the stem cells aregrown in an undifferentiated state.

The present invention also relates to the method, wherein themesenchymal stem cells are subcultured at the point in time when thedensity of the cells in the medium reaches 5,500 cells/cm² or more.

Furthermore, the present invention relates to the method, wherein themedium is replaced at least once a week.

The present invention also relates to the method, wherein the subcultureis repeated until the total number of the cells reaches 100,000,000cells or more.

The present invention relates to isolated cultured human cells culturedby any of the methods, characterized in that the cells are free fromCD24 expression.

The present invention also relates to isolated cultured human cellscultured by any of the methods, characterized in that the cells haveexpression of at least 90% of CD antigens in a positive group describedin Table 1 and are free from expression of at least 90% of CD antigensin a negative group described therein.

The cells are further characterized in that the cells are free fromaberrant expression of all of various cancer-related genes whoseexpression in humans is not preferable, for example, EWI-FLI-1,FUS-CHOP, EWS-ATF1, SYT-SSX1, PDGFA, FLI-1, FEV, ATF-1, WT1, NR4A3,CHOP/DDIT3, FUS/TLS, BBF2H7, CHOP, MDM2, CDK4, HGFR, c-met, PDGFα, HGF,GFRA1, FASN, HMGCR, RGS2, PPARγ, YAP, BIRC2, lumican, caldesmon, ALCAM,Jam-2, Jam-3, cadherin II, DKK1, Wnt, Nucleostemin, Neurofibromin, RB,CDK4, p16, MYCN, telomere, hTERT, ALT, Ras, TK-R, CD90, CD105, CD133,VEGFR2, CD99, ets, ERG, ETV1, FEV, ETV4, MYC, EAT-2, MMP-3, FRINGE, ID2,CCND1, TGFBR2, CDKNIA, p57, p19, p16, p53, IGF-1, c-myc, p21, cyclin D1,and p21. This aberrant expression means expression significantly higherthan the corresponding expression level in healthy individuals.

The present invention relates to a method for producing a pharmaceuticalpreparation for tissue repair/regeneration using the cells.

Moreover, the present invention relates to a pharmaceutical preparationfor tissue repair/regeneration comprising the cells.

The present invention relates to the pharmaceutical preparation forassisting in the repair of an injury site or for assisting in the repairof an aged site attributed to aging, wherein the cells are mesenchymalstem cells, and the pharmaceutical preparation is administeredintravenously, via lumbar puncture, intracerebrally,intracerebroventricularly, locally, or intraarterially. The tissue isnot particularly limited and can be exemplified by tissues of thenervous system including brain or spinal cord, kidney, pancreas, liver,intestine, stomach, digestive organs, lung, heart, spleen, bloodvessels, blood, skin, bone, cartilage, teeth, and prostate. The cellsare preferably autologous cells.

In a preferable embodiment, the pharmaceutical preparation for tissuerepair/regeneration of the present invention is administered in thesubacute phase or later of disease or disorder and assists in the repairof an injury site by cytokine secretion, angiogenesis, and/or nerveregeneration.

In one embodiment, the injury site is kidney, and the pharmaceuticalpreparation promotes the repair of the injury site by improvement in BUNvalue and/or creatinine value.

In one embodiment, the injury site is pancreas, and the pharmaceuticalpreparation promotes the repair of the injury site by improvement inblood-sugar level, serum Glu A1 concentration, and/or serum HbA1Cconcentration.

In one embodiment, the injury site is heart, and the pharmaceuticalpreparation promotes the repair of the injury site by improvement inserum prostaglandin D synthase concentration and/or serum homocysteineconcentration.

In one embodiment, the injury site is liver, and the pharmaceuticalpreparation promotes the repair of the injury site by improvement in GOTvalue, GPT value, and/or y-GTP value.

In one embodiment, the injury site is brain, and the pharmaceuticalpreparation can treat aphasia or dementia by promoting improvement inSLTA value serving as an index for aphasia and/or WAIS-R value servingas an index for intellectual recovery.

In one embodiment, the injury site is prostate, and the pharmaceuticalpreparation promotes the repair of the injury site by improvement in PSAvalue.

Examples of the disease or disorder targeted by the pharmaceuticalpreparation for tissue repair/regeneration of the present invention canspecifically include, but not limited to, kidney damage, liver damage,pancreatic disorder including diabetic mellitus, benign prostatichyperplasia, hyperlipemia, higher brain dysfunction including aphasiaand dementia, post- resuscitation encephalopathy, heart disease, andspinal cord injury.

The present invention also relates to a kit for preparing the cells ofthe present invention, the kit comprising a container filled with amedium characterized by containing an anticoagulant in an amount lessthan 0.5 U/mL. The kit may comprise other reagents, instruments, ormaterials necessary for preparing the cells. For example, heparin isused as the anticoagulant, if any, in the kit.

Furthermore, the present invention also relates to cell therapy fortissue repair/regeneration comprising the steps of: culturing, by themethod of the present invention, cells isolated from a subject;examining the cells obtained in the preceding step, for their expressionof cancer-related genes; and administering, to the subject, cellsconfirmed in the examination to be safe. In this context, examples ofthe cancer-related genes to be examined can include those exemplifiedabove.

In a preferable aspect, the cell therapy is treatment of ischemicneurological disease wherein the tissue is a tissue of the nervoussystem, and the cells are autologous mesenchymal stem cells and areadministered intravenously, via lumbar puncture, intracerebrally,intracerebroventricularly, or intraarterially.

ADVANTAGES OF THE INVENTION

The present invention achieves significant improvement in growth rateeven using allogeneic serum (e.g., autoserum of a subject from whichcells are collected) instead of foreign serum (FBS) in culture, evenwhen an anticoagulant conventionally considered to be essential oruseful for cell growth is added in a trace amount or is substantiallyabsent. In addition, according to the present invention, cells havingexcellent growth efficiency (growing quickly) are obtained. Thesesurprising effects have been totally unexpected from the conventionalwisdom. The cells obtained by the culture method free from autoserum aremuch more excellent in safety and differentiation potency than thoseobtained by the conventional culture method without using FBS.

A pharmaceutical preparation of the present invention has therapeuticeffects even when administered in the subacute phase or later ofdisease, which has been assumed to be ineffective for administration.Therefore, the cells to be administered do not have be prepared beforethe development of the disease and need only to be collected from asubject after the development and cultured. Thus, the pharmaceuticalpreparation of the present invention can drastically reduce the burdenof the subject. Moreover, the pharmaceutical preparation of the presentinvention can assist, by intravenous injection, in the repair of anarbitrary injury site in the body and therefore, is less invasive to thesubject. Moreover, the pharmaceutical preparation of the presentinvention can be administered in a usual treatment room or the like,without surgery and therefore, can reduce the burden of medical donorsand medical cost. Furthermore, the pharmaceutical preparation of thepresent invention has repair-assisting effects on a plurality ofdifferent tissues and is therefore applicable in a wider range.Particularly, the pharmaceutical preparation of the present inventioncan simultaneously and effectively treat a plurality of different injurysites in the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing the growth of human mesenchymal stem cellswhen the amount of heparin added to a bone marrow fluid was 0.1 U/mL (♦)or 267 U/mL (▪);

FIG. 2 is a graph showing the number of cells after 4 days into culturewhen a trace amount (left) or 2 mL (right) of heparin was added to thebone marrow fluid. The number of cells was about 40 times higher by theaddition of trace heparin;

FIG. 3 is a graph showing a mesenchymal stem cell growth in a mediumsupplemented with human adult serum (♦) or FBS (▪) when the amount ofheparin added was 0.1 U/mL;

FIG. 4 is a graph showing a growth rate when rat mesenchymal stem cellswere cultured in a medium containing 10% FBS supplemented with varyingamounts of heparin (1 U/mL, 10 U/mL, 100 U/mL, and 1000 U/mL in thisorder from top to down);

FIG. 5 is a graph showing a growth rate when rat mesenchymal stem cellswere cultured in a medium supplemented with heparin (♦) or when the sameamount of heparin thereas was added to a bone marrow fluid, followed byculture in a medium (▪);

FIG. 6 is a graph showing the growth of human mesenchymal stem cells inan αMEM medium supplemented with either human adult autoserum (solidline) or FBS (dotted line) when the amount of heparin added was 0.1U/mL;

FIG. 7 is a graph showing the growth of human mesenchymal stem cellsobtained by the addition of glutamine (♦) or in the absence of glutamine(▪) when the amount of heparin added was less than 0.1 U/mL;

FIG. 8 is a graph showing a growth rate when rat mesenchymal stem cellsuntreated with heparin (♦), treated with heparin (▪), or treated withheparin+protamine (▴) were cultured in an FBS-containing medium;

FIG. 9 is a diagram showing the therapeutic mechanism of apharmaceutical preparation of the present invention. The ordinaterepresents the severity of symptoms. The abscissa represents the timelapsed from the development. The arrow represents the timing ofadministration of the pharmaceutical preparation of the presentinvention. The upper curve located on the right side of the arrowrepresents changes in the symptoms of a subject that received theadministration of the preparation. The lower curve represents changes inthe symptoms of a subject that did not receive the administration;

FIG. 10 is an MRI image of the brain of an ischemic neurological diseasepatient before administration of the pharmaceutical preparation of thepresent invention (left) and after 2 weeks of administration (right).The injury site is indicated in white portion;

FIG. 11 is a graph showing changes in the cerebral infarction level(NIHSS: National Institutes of Health Stroke Scale (●), JSS: JapanStroke Scale (▪), and MRS: Modified Ranking Scale (▴)) of an ischemicneurological disease patient during the period centering onadministration of the pharmaceutical preparation of the presentinvention. The arrow represents the timing of administration of thecells;

FIG. 12 is a thermographic image of an ischemic neurological diseasepatient before administration of the pharmaceutical preparation of thepresent invention (left) and after 1 week of administration (right). Thedeep color region representing a high temperature was significantlyreduced after 1 week of administration;

FIG. 13 is a graph showing changes in the blood-sugar level (BS: ●),serum Glu A1 concentration (▪), and serum HbA1C concentration (▴) of adiabetic mellitus patient before and after administration of thepharmaceutical preparation of the present invention. The left and rightordinates represent mg/dl and %, respectively. The abscissa represents adate with the administration day as day 0. The arrow represents thetiming of administration of the cells (the pharmaceutical preparation ofthe present invention);

FIG. 14 is a graph showing changes in the PSA value of a benignprostatic hyperplasia patient before and after administration of thepharmaceutical preparation of the present invention. The arrowrepresents the timing of administration of the cells (the pharmaceuticalpreparation of the present invention);

FIG. 15 is a graph showing changes in the γ-GTP (left), GOT (right: ♦),and GPT (right: ▪) values of a liver damage patient before and afteradministration of the pharmaceutical preparation of the presentinvention. The arrow represents the timing of administration of thecells (the pharmaceutical preparation of the present invention);

FIG. 16 is a graph showing changes in the β2-microglobulin value of akidney damage patient before and after administration of thepharmaceutical preparation of the present invention. The arrowrepresents the timing of administration of the cells (the pharmaceuticalpreparation of the present invention);

FIG. 17 is a graph showing changes in the neutral fat of a hyperlipemiapatient before and after administration of the pharmaceuticalpreparation of the present invention. The arrow represents the timing ofadministration of the cells (the pharmaceutical preparation of thepresent invention);

FIG. 18 is a graph showing changes in the SLTA and WAIS-R test resultsof a higher brain dysfunction patient (dementia and aphasia) before andafter administration of the pharmaceutical preparation of the presentinvention;

FIGS. 19A and 19B show results of comparing therapeutic effects broughtabout by administration of the pharmaceutical preparation of the presentinvention on rat cerebral infarction models, wherein the comparison wasconducted among groups from the aspects of MRI (FIG. 19A) andangiogenesis (FIG. 19B). In the diagram, the bars represent (i) auntransplanted group, (ii) a cell (1.0×10⁶)-intravenously injectedgroup, (iii) an angiopoietin gene-transfected-cell(1.0×10⁶)-intravenously injected group, (iv) a VEGFgene-transfected-cell (1.0×10⁶)-intravenously injected group, and (v) anangiopoietin/VEGF gene-transfected-cell (1.0×10⁶)-intravenously injectedgroup from left to right:* p<0.05, ** p<0.01;

FIG. 20 shows results of comparing therapeutic effects brought about byadministration of the pharmaceutical preparation of the presentinvention on rat cerebral infarction models, wherein the comparison wasconducted among groups from the behavioral aspects. In the diagram, thebars represent (i) a untransplanted group, (ii) a cell(1.0×10⁶)-intravenously injected group, (iii) an angiopoietingene-transfected-cell (1.0×10⁶)-intravenously injected group, (iv) aVEGF gene-transfected-cell (1.0×10⁶)-intravenously injected group, and(v) an angiopoietin/VEGF gene-transfected-cell (1.0×10⁶)-intravenouslyinjected group from left to right:* p<0.05, ** p<0.01;

FIGS. 21A and 21B show results of evaluating therapeutic effects broughtabout by administration of the pharmaceutical preparation of the presentinvention on rat cardiopulmonary arrest models (post-resuscitationencephalopathy), wherein the evaluation was conducted based on thenumber of Tunnel-positive cells (FIG. 21A) and the number of neuroncells (FIG. 21B). In the diagram, the left and right bars represent acontrol group and a cell-administered group, respectively: * p<0.05;

FIG. 22 show results of evaluating therapeutic effects brought about byadministration of the pharmaceutical preparation of the presentinvention on rat cardiopulmonary arrest models, wherein the evaluationwas conducted according to Morris water maze test (* p<0.05); and

FIG. 23 is a graph showing results of evaluating recovery in the motorfunction of spinal cord injury model rats transplanted with the humanmesenchymal stem cells according to the present invention, wherein theevaluation was conducted according to Treadmill test. In the diagram,the bars represent transplantation after 6 hours, 1 day, 3 days, 7 days,and 14 days from left to right.

The present specification encompasses the contents described in thespecifications of Japanese Patent Application Nos. 2007-235436 (issuedon Sep. 11, 2007), 2007-236499 (issued on Sep. 12, 2007), 2007-267211(issued on Oct. 12, 2007), 2007-278049 (issued on Oct. 25, 2007), and2007-278083 (issued on Oct. 25, 2007) that serve as the basis for thepriority of the present application.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, a cell growth method according to the present inventionwill be described in detail.

The method of the present invention is a method for growing cells in asample collected from a living subject by culturing the cells in amedium, the method characterized by comprising culturing the cells,without substantial contact with an anticoagulant, in a mediumcontaining allogeneic serum. In this context, it is preferred that theallogeneic serum should have been determined to be negative for a serumtumor marker and/or an infectious factors. Moreover, it is preferredthat the allogeneic serum should be autoserum of the subject from whichthe cells are collected.

In this context, examples of the serum tumor marker to be examined inthe present invention can include ferritin, CEA, AFP, BFP, CA125,CA15-3, CA19-9, CA72-4, STN, DUPAN-2, SLX, ST-439, SPAN-1, SCC, PSA,G-seminoprotein, TPA, CYFRA, PAP, NSE, C-peptide, PIVKA, Pro-GRP, HCGβ,elastase, β2 microglobulin, S-NTX, an anti-p53 antibody, and HER2.Examples of the infectious factors can include HIV, ATL, HB, HC,syphilis, and human parvovirus B19.

The sample used in the present invention is a bodily fluid and/or atissue containing cells that have the ability to grow and/or are usefulfor tissue repair/regeneration. Examples thereof include: bodily fluidssuch as a bone marrow fluid, blood (peripheral blood or cord blood), andlymph; tissues such as muscle tissues, bone tissues, skin, lymphoidtissues, vascular channels, and digestive organs; and embryos (exceptfor human embryos). The sample collected from a living subject issubjected as the whole sample or, if necessary, after treatment (e.g.,removal of unnecessary components, purification of a particular cellfraction, and enzymatic treatment) to the growth method according to thepresent invention.

In the present specification, the phrase “without substantial contact(of the cells) with an anticoagulant” means that the anticoagulant isused in a substantially decreased amount at any point in time from cellcollection to the whole culture period. For example, this means a stateobtained when: the anticoagulant is added to the degree where the innerwall of a container for cell collection (blood collection tube, etc.) iswetted with an anticoagulant solution; no anticoagulant is added; or theanticoagulant in the sample is substantially removed before the start ofculture.

For obtaining more rapid and massive cell growth, it is preferred thatthe amount of the anticoagulant added during sample collection should besmall. For avoiding coagulation, the collected cells are shiftedimmediately (e.g., within 30 minutes) after collection to the culturestep. More preferably, the cells are kept from substantial contact withthe anticoagulant. These procedures produce a surprisingly high growthrate, which is 3 to 100 times higher than a conventional one.

In a preferable aspect of the present invention, the amount of theanticoagulant added to the sample collected from a living subject (i.e.,previously placed in a blood collection tube for containing thecollected sample) is less than 5 U/mL, preferably, less than 2 U/mL,even more preferably, less than 0.2 U/mL, with respect to the volume ofthe sample.

In another preferable aspect of the present invention, the amount of theanticoagulant present in the medium during culture of the cells in thesample collected from a living subject is less than 0.5 U/mL,preferably, less than 0.2 U/mL, most preferably, less than 0.02 U/mL,with respect to the volume of the medium. More specifically, the amountof the anticoagulant added to the blood collection tube for samplecollection is reduced in advance and/or the amount of the anticoagulantadded to the medium is adjusted such that the amount of theanticoagulant at the start of culture is less than 0.5 U/mL with respectto the volume of the medium.

Moreover, in the present specification, the term “anticoagulant” refersto a substance that, when present in the bodily fluid or the medium,interacts through binding to cell surface with extracellular matrixproteins having anti-blood coagulation effects and inhibits the adhesionbetween the cells and the extracellular matrix, between the cells, orbetween the cells and substrates. For example, heparin and a heparinderivative (e.g., glycosaminoglycan obtained by desulfation at position6 of D-glucosamine constituting heparin; disclosed in Japanese PatentLaid-Open No. 2005-218308A), or a salt thereof are typically used.

In the method of the present invention, the medium for cell growth isnot particularly limited as long as the medium is usually used in thefield of cell culture. For obtaining more rapid and massive growth, aserum-containing medium is preferable. The serum-containing medium usedis based on a standard medium as described below in other paragraphsherein and is prepared by adding serum in an amount less than 12% to themedium. The smaller amount of serum is more preferable in considerationof the burden of an individual as a serum donor. The amount of the serumis preferably 1% to 20% by volume, more preferably 3 to 12%, even morepreferably 5 to 10%, in consideration of a range that produces thedesired effect of rapidly promoting cell growth.

In the method of the present invention, the serum used is serum of amammal and serum of an individual from which the cells are derived(autoserum). However, when the cells to be cultured are human cells,autoserum may be difficult to collect. In such a case, as long as thecells are cultured without substantial contact with the anticoagulant,high growth efficiency can be achieved even using foreign animal serum(e.g., FBS) or serum of another individual of the same species as thehuman (allologous serum). However, the effects of the present inventionbrought about by the absence of the anticoagulant are obtained moresignificantly by use of human serum than by use of, for example, FBS.The serum may be serum derived from peripheral blood or may be serumderived from cord blood.

The cells to be grown by the method of the present invention need onlyto be cells that are prepared from a sample containing blood componentsand adhesion-cultured. Examples thereof include, but not limited to:somatic stem cells such as mesenchymal cells, mesenchymal stem cells,hematopoietic stem cells, cord blood stem cells, corneal stem cells,hepatic stem cells, and pancreatic stem cells; embryonic stem cellmonocytes (except for human embryos) such as fetal stem cells; andosteoblasts, fibroblasts, ligament cells, epithelial cells, and vascularendothelial cells.

In one aspect, the method of the present invention is suitable for stemcell growth and is used, for example, for growing mesenchymal stemcells.

The mesenchymal stem cells are stem cells that are present in a traceamount in interstitial cells in mesenchymal tissues and havepluripotency and the ability to self-replicate. The cells have beenfound in recent years not only to differentiate into connective tissuecells such as bone cells, cartilage cells, and fat cells but also tohave differentiation potency into neuron cells or myocardial cells.

In one aspect, the method of the present invention may be used forgrowing human cells.

In another aspect of the present invention, the cells to be grown may becells of animals other than humans (e.g.: rodents such as mice, rats,guinea pigs, and hamsters; primates such as chimpanzees; animals of theArtiodactyla such as cow, goats, and sheep; animals of thePerissodactyla such as horses; and rabbits, dogs, and cats).

Furthermore, in one aspect of the method of the present invention, thestem cells may be grown in an undifferentiated state.

In general, stem cells in an undifferentiated state have a higher growthrate and a higher survival rate after introduction into living subjects.For example, for the treatment of ischemic brain disease, which requiresrapid and massive cell growth, the collected stem cells can be grown tothe necessary number in a short period by growing them in anundifferentiated state.

Alternatively, when cells differentiated into a given cell species aredesired, stem cells or blast cells may be grown massively in anundifferentiated state and subsequently induced to differentiate intothe desired cell species, for example, by the addition of a known growthfactor inducing such differentiation or by the transfection of a genehaving such properties, to obtain a large amount of differentiatedcells.

In one aspect of the present invention, it is preferred that themesenchymal stem cells should be subculture at the point in time whenthe density of the cells in the medium reaches 5,500 cells/cm² or more.

The density of the cells in the medium influences cell properties andthe direction of differentiation. For example, in culture of themesenchymal stem cells, the cell properties are altered when the densityof the cells in the medium exceeds 8,500 cells/cm². Therefore, it ispreferred that the cells should be subculture at a cell density of 8,500cells/cm² or less at maximum, more preferably, at the point in time whenthe cell density reaches 5,500 cells/cm² or more.

Moreover, in a preferable aspect of the present invention, the medium isreplaced at least once a week.

The medium replacement is required for supplying a nutrient, a growthfactor, a growth-promoting substance, and the like necessary for cellculture and growth and for removing waste products such as lactic acidformed by cell metabolism and thereby maintaining the pH of the mediumat a constant level. The medium replacement is performed with a periodselected depending on the type of the cells, culture conditions, and soon. Particularly, when a human serum-containing medium is used, fewermedium replacements are more desirable in consideration of the burden ofthe serum donor. For example, when the mesenchymal stem cells arecultured by the method of the present invention, medium replacement isperformed at least once a week, more preferably once to twice a week.The method of the present invention reduces a culture period required toobtain the necessary number of cells. Therefore, the amount of serumused by medium replacement can be reduced.

In a preferable aspect of the method of the present invention, thesubculture can be repeated until the total number of the cells reaches100,000,000 cells or more.

Cell culture using the method of the present invention produces a growthrate 3 to 100 times higher than a usual one. Therefore, the cells can beobtained massively in a short period. The necessary number of cells candiffer depending on the use purpose of the cells. For example, thenumber of mesenchymal stem cells required for transplantation for thetreatment of ischemic brain disease attributed to cerebral infarction isthought to be 10,000,000 cells or more. The use of the method of thepresent invention can typically offer 10,000,000 mesenchymal stem cellsin 12 days. Such a rapid cell growth has not been achieved so far andhas been achieved for the first time by the method of the presentinvention. In addition, the cells themselves obtained by this methodhave excellent growth efficiency. It is surprising to those skilled inthe art that culture in a serum-containing medium substantially freefrom heparin can offer cells having such rapid cell growth or highgrowth efficiency (quick growth).

The cells obtained by the method of the present invention are safe withhigh differentiation potency. The present inventors designated the cellsas “somatic fundamental stem cells”. The “somatic fundamental stemcells” obtained by the method of the present invention containparticular genes with different expression levels (the presence orabsence of expression or reduced/increased expression) from those incells obtained by culture using foreign serum (e.g., FBS).

For example, Table 1 shows the group of cell surface antigens (CDantigens) expressed in the autoserum-cultured cells and the group of CDantigens not expressed in the autoserum-cultured stem cells. The cellsobtained by the method of the present invention are characterized inthat at least 90% of CD antigens in a positive group described in Table1 are expressed and at least 90% of CD antigens in a negative grouptherein are not expressed in the cells. The cells obtained by the methodof the present invention are characterized in that the differentiationmarker CD 24 expressed in foreign serum (e.g., FBS)-cultured cells arenot expressed. This shows that the cells according to the presentinvention maintain a more undifferentiated state.

Table 3 shows cytokines that exhibited increased or decreased expressionin common in the 5 cases. Furthermore, Table 4 shows a gene group whoseexpression level differed by two times or more in common in the 5 cases.As shown in these tables, a series of growth factors are expressed inthe cells obtained by the method of the present invention, and,particularly for EGF, its expression level is higher therein than thatin a culture method using foreign serum (e.g., FBS). This probablysuggests the cause for the advantage of the cells of the presentinvention to growth.

Furthermore, Table 2 shows growth factor-related factors that exhibitedincreased or decreased expression in common in the 5 cases involving theFBS-cultured cells and the autoserum-cultured cells. As shown in thistable, the cells obtained by the method of the present invention haslower expression of a cancer-related gene group or a lower expressionlevel thereof than that obtained in a culture method using foreign serum(e.g., FBS). Examples of the cancer-related genes that are notpreferable can include EWI-FLI-1, FUS-CHOP, EWS-ATF1, SYT-SSX1, PDGFA,FLI-1, FEV, ATF-1, WT1, NR4A3, CHOP/DDIT3, FUS/TLS, BBF2H7, CHOP, MDM2,CDK4, HGFR, c-met, PDGFα, HGF, GFRA1, FASN, HMGCR, RGS2, PPARγ, YAP,3IRC2, lumican, caldesmon, ALCAM, Jam-2, Jam-3, cadherin II, DKK1, Wnt,Nucleostemin, Neurofibromin, RB, CDK4, p16, MYCN, telomere, hTERT, ALT,Ras, TK-R, CD90, CD105, CD133, VEGFR2, CD99, ets, ERG, ETV1, FEV, ETV4,MYC, EAT-2, MMP-3, FRINGE, ID2, CCND1, TGFBR2, CDKNIA, p57, p19, p16,p53, IGF-1, c-myc, p21, cyclin D1, and p21.

In the present specification, the term “decreased (or increased)expression level” is intended to mean that “Signal Log Ratio” based onalgorithm well known in the art (GeneChip Algorithm (AFFYMETRIX, Inc.)is “−1≤” or “1≤” (i.e., the ratio of the gene expression level betweenbaseline and experiment arrays is two times or more (Table 5)), morepreferably, “−2≤” or “2≤” (i.e., the ratio of the gene expression levelbetween baseline and experiment arrays is four times or more). The term“gene described in the table” used herein is intended to mean a geneidentified by “Probe Set ID” described in this table (this gene includesvariants that retain the functions of the gene). These genes correspondto genes represented by Gene Symbol. The Gene Symbol is a name uniquelyassociated with each gene by NCBI, US. The details of the Probe Set IDand the Gene Symbol are described in the NetAffx database of AFFYMETRIX,Inc. and easily understood by those skilled in the art. The term“variants” used for genes is used exchangeably with the term “genevariants” and intended to mean any of (i) those comprising a nucleotidesequence derived from the nucleotide sequence of the identified gene bythe deletion, substitution, or addition of one or more bases, (ii) thosecomprising a nucleotide sequence capable of hybridizing under stringentconditions to the identified gene, and (iii) those comprising anucleotide sequence having at least 80% identity to the nucleotidesequence of the identified gene. All of these variants retain thefunctions of the identified gene. The term “gene functions” used hereinis used exchangeably with the term “functions of a protein encoded bythe gene”. A protein encoded by the “gene described in the table” is aprotein having well known functions, and assay systems for confirmingthe functions are also well known in the art. Accordingly, those skilledin the art can use techniques well known in the art to easily preparesuch gene variants and to easily confirm their functions. For example,the specific procedures of hybridization and the “stringent”hybridization conditions can be performed according to methods wellknown in the art, such as methods described in “Molecular Cloning: ALaboratory Manual, 3rd edition, J. Sambrook and D. W. Russell, ed., ColdSpring Harbor Laboratory, NY (2001)” (incorporated herein by reference).

In the present invention, it is intended that the group of CD antigensis confirmed to be “expressed” or “not expressed” based on resultsobtained using Analysis mode in GeneChip Operating Software (GCOS) ofAffymetrix, Inc. Moreover, proteins encoded by the gene variants thatretain the functions of the gene described in the table can be variantsof the protein encoded by the gene described in the table. The term“variants” used for proteins is used exchangeably with the term “proteinvariants” and intended to mean those comprising an amino acid sequencederived from the amino acid sequence of the protein encoded by theidentified gene, by the deletion, substitution, or addition of one ormore amino acids. Those skilled in the art can also use techniques wellknown in the art to easily prepare such protein variants and to easilyconfirm their functions.

The cells according to the present invention are cells having theability to grow available for use in tissue repair and regeneration.Examples of donor cells used in tissue repair and regeneration includeautologous or allologous tissue stem cells or somatic stem cells, orembryonic stem cells. Accordingly, the cells according to the presentinvention can be cells derived from tissue stem cells, somatic stemcells, or embryonic stem cells. The cells according to the presentinvention are preferably autologous cells, particularly, cells derivedfrom somatic stem cells (e.g., bone marrow cells) that can noninvasivelysecure donor cells, in consideration of ethical problems, infectionrisk, need to use immunosuppressive agents, and so on.

The tissue stem cells, somatic stem cells, or embryonic stem cells canbe supplied from the tissue or bodily fluid of a mammal individual.Examples of the tissue preferable as a source of these cells includemuscle tissues, bone tissues, fat tissues, skin, lymphoid tissues,vascular channels, digestive organs, hair roots, dental pulps, andembryos (except for human embryos). Examples of the bodily fluidpreferable as a source include a bone marrow fluid, blood (peripheralblood or cord blood), and lymph. Particularly, when a subject to berepaired and regenerated is tissue of the nervous system, examples ofthe source of the donor cells include bone marrow, peripheral blood,cord blood, fetal embryos, and brain. When a subject to be repaired andregenerated is a hematopoietic tissue, examples of the source includebone marrow, peripheral blood, cord blood, and fetal embryos. Thoseskilled in the art can use techniques well known in the art to easilyprepare the intended cells.

The cells according to the present invention are cells available for usein tissue repair and regeneration and are therefore, preferably,adherent cells, more preferably cells derived from, for example: somaticstem cells such as mesenchymal cells, mesenchymal stem cells,hematopoietic stem cells, cord blood stem cells, corneal stem cells,hepatic stem cells, and pancreatic stem cells; embryonic stem cellmonocytes (except for human embryos) such as fetal stem cells; andosteoblasts, fibroblasts, ligament cells, epithelial cells, and vascularendothelial cells. For the purpose of using the cells in the treatmentof neurological disease in the acute phase, it is preferred that thecells according to the present invention should be derived from stemcells, particularly, mesenchymal stem cells. The mesenchymal stem cellsare stem cells that are present in a trace amount in interstitial cellsin mesenchymal tissues and have pluripotency and the ability toself-replicate. The cells have been found in recent years not only todifferentiate into connective tissue cells such as bone cells, cartilagecells, and fat cells but also to have differentiation potency intoneuron cells or myocardial cells. In this context, stem cells in anundifferentiated state have a higher growth rate and a higher survivalrate after introduction into living subjects. Therefore, it is preferredthat the cells according to the present invention should be cells in anundifferentiated state derived from stem cells.

The cells according to the present invention are preferablyhuman-derived cells and may be cells derived from mammals other thanhumans (e.g.: rodents such as mice, rats, guinea pigs, and hamsters;primates such as chimpanzees; animals of the Artiodactyla such as cow,goats, and sheep; animals of the Perissodactyla such as horses; andrabbits, dogs, and cats).

The autoserum used herein is serum of an individual from which the cellsare derived (autoserum). However, a high growth rate can also beobtained using serum of other adult humans when use of autoserum isdifficult.

As described above, the cells according to the present invention have ahigher growth rate in the presence of allogeneic serum, particularly,autoserum, than that in the presence of foreign serum. In addition, thecells according to the present invention are safe cells that are kept ina more undifferentiated state with high differentiation potency. Themedium used in the cell culture according to the present invention isappropriately selected from among various standard media known in theart (e.g., Dulbecco's modified eagle's medium (DMEM), NPBM, and αMEM)according to the type of the cells, the desired direction and level ofdifferentiation, a necessary growth rate, and so on. DMEM is preferablyused.

In one aspect, the cells cultured by the method of the present inventionmay be used in the production of a pharmaceutical preparation for tissuerepair/regeneration.

A therapeutic drug comprising the cells obtained by the growth method ofthe present invention as an active ingredient, when administered to asubject, can repair and regenerate a tissue as a subject that has lostits function. Particularly, when mesenchymal stem cells are used, abrain tissue in ischemic brain disease can be repaired and regenerated(see WO02/00849A1). The tissue repair and regeneration used herein aresynonymous with repair and regeneration of the functions. Thetherapeutic effects of, for example, repair/regeneration of a tissue ofthe nervous system encompass neuroprotective effects (e.g.,remyelination of axons), neurotrophic effects (e.g., replenishment ofneuroglia cells), brain angiogenesis, nerve regeneration, and so on.Specifically, the therapeutic effects of the pharmaceutical preparationcomprising the cells grown by the method of the present invention meantissue repair/regeneration as entities and repair/regeneration ofdysfunction of the tissue as phenomena. When the grown cells are usedfor tissue repair/regeneration, it is preferred that the source of thedonor cells should be confirmed in advance by peripheral bloodexamination to be not infected with HIV, ATL, HB, HC, syphilis, humanparvovirus B19, and the like.

Moreover, in one aspect, the cells grown by the method of the presentinvention may be used in the diagnosis of disease or infection withpathogens. For example, cancer risk can be diagnosed by examining thestate of cancer-related genes contained in cells that are collected froma subject and grown ex vivo.

Moreover, prion disease in a subject is difficult to detect by usualexamination methods. However, such prion disease can be diagnosed bygrowing cells by the method of the present invention and thereby rapidlyamplifying abnormal prion to a level equal to or higher than detectionsensitivity.

Alternatively, the cells grown by the method of the present inventionmay be used in in-vivo or in-vitro experiments.

Examples of the pharmaceutical preparation for tissuerepair/regeneration comprising the cells grown by the method of thepresent invention include, but not limited to, injections (e.g.,injections containing neural progenitor cells, hematopoietic stem cells,liver cells, pancreatic cells, or lymphocytic cells) and implants fortransplantation (e.g., myocardial cell sheets, artificial skin,artificial cornea, artificial dental roots, and artificial joints)comprising the cells grown ex vivo using the method of the presentinvention in combination with pharmaceutically acceptable diluents,excipients, and/or bases.

The pharmaceutical preparation comprising the cells cultured by themethod of the present invention may be used for repair/regeneration of atissue of the nervous system. For example, autologous mesenchymal stemcells may be grown and used in a pharmaceutical preparation fortreatment of ischemic neurological disease. In a preferable aspect, thecells contained in the pharmaceutical preparation are cells derived froma subject to which the cells are administered (autologous cells).

Examples of disease of the nervous system targeted by such cell therapyinclude, but not limited to, central and peripheral demyelinatingdiseases, central and peripheral degenerative diseases, cerebralapoplexy (including cerebral infarction, cerebral hemorrhage, andsubarachnoid hemorrhage), brain tumor, higher dysfunction includingdementia, psychiatric diseases, epilepsy, traumatic disease of thenervous system (including head injury, cerebral contusion, and spinalcord injury), spinal cord infraction, and prion diseases (e.g.,Creutzfeldt-Jacob disease, kuru disease, bovine spongiformencephalopathy, and scrapie).

The cells grown by the method of the present invention are also usefulfor treatment of disease other than disease of the nervous system. Forthe treatment of, for example, acute leukemia, hematopoietic stem cellsmay be grown ex vivo and transplanted in bone marrow. Usual bone marrowtransplantation typically requires 2×10⁸ cells for autotransplantationand 4×10⁸ cells for allotransplantation, per body weight of a recipient,and thus the amount of a bone marrow fluid collected from a cell donormay reach 1000 mL. However, the physical burden of the cell donor can bereduced by rapidly growing the cells ex vivo using the method of thepresent invention. Moreover, for the treatment of viral infection or thelike, T-lymphocytes collected from the peripheral blood of a patient maybe grown ex vivo using the method of the present invention andtransplanted to this patient.

The source of the donor cells used in cell replenishment for tissuerepair/regeneration can be derived from autologous or allologous tissuestem cells or somatic stem cells, or embryonic stem cells. Anautotransplantation therapy using autologous cells, particularly, cellsderived from somatic stem cells (e.g., bone marrow cells) that cannoninvasively secure donor cells is preferable in consideration ofethical problems, infection risk, and difficulty such as need to useimmunosuppressive agents. Cells derived from other humans or otheranimals may be used when the autotransplantation therapy is difficult.The donor cells may be cells contained in a sample collected immediatelybefore culture or may be cryopreserved cells as long as the amount ofthe anticoagulant contained in the sample at the start of culture isless than 5 U/mL. Alternatively, autologous cells may be grown inadvance, then cryopreserved, and administered at the time of treatmentof disease, as shown in, for example, a therapeutic model using atherapeutic cell delivery support system described in WO 2005/001732A1.

The source of the cells is desirably those containing cells alreadyknown to differentiate into a cell species of a particular tissue to berepaired/regenerated, for example, cells of the same germ layer thereasor totipotent stem cells. However, stem cells differentiated to somedegree to a different germ layer (e.g., fetal liver cells) have alsobeen found to redifferentiate into the other tissue cells such as cellsof the nervous system (e.g., cells described in WO 02/00849A1). Inconsideration of this finding, tissues containing cells of a differentgerm layer therefrom may be used as long as the cells can be induced todifferentiate into the desired cell species using adifferentiation-inducing factor or the like known in the art.

When the tissue to be repaired is a tissue of the nervous system,examples of the source of the donor cells include cells derived frombone marrow, peripheral blood, cord blood, fetal embryos, and brain.When the tissue to be repaired is a hematopoietic tissue, examples ofthe source include hematopoietic stem cells and cord blood stem cellscontained in bone marrow, peripheral blood, cord blood, or fetalembryos.

The use of bone marrow-derived mesenchymal stem cells for repair of atissue of the nervous system has, for example, the followingadvantages: 1) the cells can be expected to produce significant effects,2) they carry low risk of side effects, 3) sufficient donor cells can beexpected to be supplied, 4) they achieve noninvasive treatment andautotransplantation; thus 5) such cell therapy carries low infectionrisk, 6) it is in no danger of immune rejection, 7) it produces noethical problem, 8) it is easily socially acceptable, and 9) it iseasily established widely as general medical care. Furthermore, the bonemarrow transplantation therapy is treatment already used in clinicalpractice and has also been confirmed to be safe. Moreover, the bonemarrow-derived stem cells, which have high migration properties, canarrive at the intended injured tissue not only by local transplantationbut also by intravenous administration to exert their therapeuticeffects thereon.

The bone marrow fluid can be collected, for example, by locally orsystemically anesthetizing animals serving as a collection source(including humans) and inserting a needle into the sternum or ilium,followed by suction using a syringe. Moreover, an established techniquefor cord blood comprises directly inserting a needle into the umbilicalcord of a new-born baby, then collecting cord blood therefrom by suctionusing a syringe, and storing the collected cord blood. In conventionalmethods, an anticoagulant is used to prevent blood components from beingcoagulated in the collected bone marrow fluid. By contrast, in themethod of the present invention, such an anticoagulant does not have tobe used, as described above.

A possible method for delivering, to an injured tissue, thepharmaceutical preparation comprising the cells grown by the method ofthe present invention is, for example, local transplantation by surgicalmeans, intravenous administration, administration via lumbar puncture,administration through local injection, hypodermic administration,intradermal administration, intraperitoneal administration,intramuscular administration, intracerebral administration,intracerebroventricular administration, or venous administration.Moreover, the cells grown by the method of the present invention may becontained or seeded in implants, cell sheet bases, artificial joints, orthe like and transplanted into a living subject.

For example, when the cells are used for repair of the nervous system,the cell transplantation to a patient by injection can be performed by:filling a syringe with the cells to be transplanted, in a floating stateusing an artificial cerebrospinal fluid, saline, or the like; exposingan injured nervous tissue by surgery; and directly injecting thecontents of the syringe to this injury site. Cells having migrationproperties high enough to be movable in a tissue (e.g., cells describedin WO 02/00849A1) may be transplanted in the vicinity of an injury site.Moreover, such cells can be expected to exert their effects even byinjection into a cerebrospinal fluid. In this case, the cells can beinjected via usual lumbar puncture and are therefore preferable becausethe patient does not have to be operated and can be treated only underlocal anesthesia in a hospital room. Furthermore, the cells can also beexpected to exert their effects by intravenous injection. Thus, thecells are preferable from the viewpoint of permitting transplantation bythe manner of usual transfusion and achieving transplantation proceduresin a ward.

The medium suitable for the cell growth according to the presentinvention is selected according to the type of the cells, the desireddirection and level of differentiation, a necessary growth rate, and soon. Examples of a medium suitable for growing mesenchymal stem cellsused for repair of the nervous system include, but not limited to,Neural Progenitor Basal Medium (NPBM: manufactured by Clontech) and αMEMmedium, in addition to Dulbecco's modified eagle's medium (DMEM) shownbelow. Such a standard medium is supplemented with serum as describedabove and further supplemented, if necessary, with a nutritional factor(e.g., amino acids), an antibiotic, a growth factor and/or agrowth-promoting substance, and the like.

Specific examples of the standard medium include Dulbecco's modifiedmedia containing the following components at the followingconcentrations (mg/L):

CaCl₂ (anhydrate): 160 to 240

KCL: 320 to 480

Fe (NO₃)₃·9H₂O: 0.08 to 1.2MgSO₄ (anhydrate): 80 to 120

NaCl: 5120 to 7680 NaHCO₃: 2960 to 4440

NaH₂PO₄·H₂O: 100 to 150

D-glucose: 3600 to 5400

phenol red: 12 to 18sodium pyruvate: 88 to 132

L-arginine·HCl: 67 to 101 L-cysteine·2HCl: 50 to 76 L-histidine·HCl·H₂O:34 to 50 L-isoleucine: 84 to 126 L-leucine: 84 to 126 L-lysine·HCl: 117to 175 L-methionine: 24 to 36 L-phenylalanine: 53 to 79 L-serine: 34 to50 L-threonine: 76 to 114 L-tryptophan: 13 to 19

L-tyrosine (disodium salt): 83 to 125

L-valine: 75 to 113

choline chloride: 3.2 to 4.8D-Ca-pantothenic acid: 3.2 to 4.8folic acid: 3.2 to 4.8i-inositol: 5.8 to 8.6niacinamide: 3.2 to 4.8pyridoxal·HCl: 3.2 to 4.8riboflavin: 0.3 to 0.5thiamine·HCl: 3.2 to 4.8

If desired, antibiotics usually used in the field of cell culture (e.g.,penicillin and streptomycin) may be used alone or in combination.Combined use of a plurality of antibiotics is preferable. For example,when penicillin and streptomycin are used in combination, their amountsare respectively 0.5 to 2% by volume, preferably 0.8 to 1.2% by volume,with respect to the volume of the medium.

Examples of low-molecular amino acids contained in the medium includeL-alanine, L-aspartat, L-cysteine, L-glutamine, L-isoleucine,L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine,L-tyrosine, L-valine, L-ascorbic acid, and L-glutamic acid. These aminoacids are contained as nutrients in a medium usually used in the fieldof cell culture.

Furthermore, the present inventors have found that the addition ofglutamine in an amount of 0.1 to 2% (weight/volume) of the whole amountof the medium is essential for rapid growth of the mesenchymal stemcells and further found that the replenishment of glutamine to keep theamount of 0.1 to 2% (weight/volume) in the medium further promotes rapidgrowth.

The standard medium may be supplemented, if necessary, with a growthfactor, a growth-promoting substance, and/or a differentiation-inducingfactor. The growth factor, the growth-promoting substance, and thedifferentiation-inducing factor are selected according to the desireddirection and level of differentiation, a necessary growth rate, and soon. Examples thereof include, but not limited to: vitamins such asascorbic acid and nicotinamide; neurotrophic factors such as NGF andBDNF; osteogenic factors such as BMP; and cytokines such as epithelialcell growth-promoting substances, basic fibroblast growth-promotingsubstances, insulin-like growth-promoting substance, and IL-2.

The cell culture method of the present invention is specificallyperformed, for example, as follows:

1. A sample collected from a living subject using a syringe whose innerwall is wetted with a heparin solution as described above is added at adilution ratio on the order of 100-fold or less, preferably 10-fold orless, more preferably approximately 2-fold to 6-fold, to a medium keptin advance at 37±0.5° C. The solution is then seeded to a culture dishand incubated at 37±0.5° C. in 5% CO2. The medium is replaced at leastonce a week, typically once to twice a week. The medium is prepared byadding serum and necessary aids to a suitable standard medium, thensterilized using a filtration sterilizer, and divided to small portions,which are then stored in a cool box at 4° C. The medium is kept at37±0.5° C. in advance and then used. At a temperature exceeding 37.5°C., the increased number of cells is dead. By contrast, at a temperaturelower than 36.5° C., the cells grow slowly. The CO2 concentration ispreferably in the range of 5±1%. In all steps, a solution contacted withthe cells is kept in this temperature range. As a result, rapid growthis promoted.2. The cells are confirmed to adhere to the culture dish base. Then, themedium and blood cell components floating in the medium are separatedand removed by suction. Subsequently, the surface of the adherent stemcells is washed with phosphate- buffered saline as a wash.3. The cells are subcultured at the point in time when the density ofthe cells in the dish reaches 5,500 cells/cm² or more, as a guideline,i.e., at the point in time when the cells reach 60 to 80%, preferably 65to 75% of confluence so as not to exceed a cell density of 8,500cells/cm². For the subculture, a dissociation agent composed mainly oftrypsin and optionally EDTA (ethylenediaminetetraacetate) is added in anamount of 3 mL/dish. After incubation at 37±5° C. for 3 to 5 minutes,the adherent stem cells are confirmed to be dissociated from the dish.The medium is replaced with a separation solution by decantation, andthe cells in the medium are transferred to a predetermined centrifugetube and sedimented by centrifugation, followed by subculture. The cycleinvolving culture, medium replacement, and subculture is repeated atleast until the total number of the mesenchymal stem cells reaches100,000,000 cells or more. The medium replacement is performed at leastonce a week.

This cycle is repeated to rapidly obtain the intended number of cells(e.g., for mesenchymal stem cells, 1×10⁸ cells can be obtained within 2weeks).

If desired, a cell scaffold material may be used for facilitating thedissociation of the cells after growth. Preferable examples of thescaffold material include, but not limited to, porous inorganicceramics, micropillar (e.g., Nanopillar Cell Culture Sheet manufacturedby Hitachi, Ltd.), nonwoven cloth, and honeycomb membrane films.

In one aspect of the present invention, the cells to be cultured may betransfected in advance with, for example, genes that induce growth anddifferentiation, such as BDNF, PLGF, GDNF, or IL-2 genes. Alternatively,the cells to be cultured may be immortalized cells transfected withimmortalizing genes such as telomerase genes. The transfection of suchgenes is disclosed in, for example, WO03/038075A1.

Those skilled in the art can select, without problems, a combinationthat produces the desired growth rate and/or induces differentiationinto a particular cell species, from among the media, the scaffoldmaterials, the aids, the growth factors, and/or the gene transfectionexemplified above.

The cells grown by the method of the present invention can beadministered directly for tissue repair/regeneration. For improvingtherapeutic efficiency, the cells may be administered or transplanted asa composition arbitrarily supplemented with various agents or after genetransfection. Examples of possible approaches for this purpose include,but not limited to: addition of substances further improving a growthrate, in a tissue, of the cells grown by the method of the presentinvention, substances promoting their differentiation into the desiredcells, or substances improving their survival rate in a tissue and/ortransfection with genes having such effects; addition of substanceshaving the effect of blocking the bad influence of a biological tissueon the transplanted cells and/or transfection with genes having sucheffects; addition of substances prolonging the life of donor cellsand/or transfection with genes having such effects; addition ofsubstances adjusting the cell cycle and/or transfection with geneshaving such effects; addition of substances intended to inhibitimmunocytes and/or transfection with genes having such effects; additionof substances activating energy metabolism and/or transfection withgenes having such effects; addition of substances improving thechemotactic activity of donor cells in a tissue and/or transfection withgenes having such effects; and addition of substances improving bloodflow and/or transfection with genes having such effects.

The cell culture is preferably performed in a cell processing center(CPC) according to GMP. It is preferred that a “clinical grade of cells”to be administered to a subject should be prepared in a special facilitydesigned for cell manipulation in a sterile state, more specifically,CPC having cleanliness secured using air conditioning, control ofchamber pressure, control of temperature and humidity, particlecounters, HEPA filters, and so on. Moreover, it is preferred thatperformance should be secured by validation not only for the CPCfacility itself but also for all instruments used in CPC and theirfunctions should always be monitored and recorded. It is desired thatall cell processing procedures in CPC should be controlled and recordedstrictly according to the “standard manual”.

The pharmaceutical preparation of the present invention may contain, asa cell component, a cell species other than mesenchymal stem cells.However, it is preferred that the mesenchymal stem cells should occupy ahigh proportion to the cell components. Thus, in a preferable aspect ofthe pharmaceutical preparation of the present invention, the proportionof the number of the mesenchymal stem cells to the total number of cellscontained in the pharmaceutical preparation is 50% or more, preferably75% or more, more preferably 80% or more, even more preferably 90% ormore, further preferably 95% or more, particularly preferably 98% ormore. Most preferably, the medium is substantially free from a cellspecies other than mesenchymal stem cells, for example, hematopoieticstem cells. The proportion of the mesenchymal stem cells to the cellcomponents can be determined easily, for example, by labeling the cellscontained in the pharmaceutical preparation with labeling antibodiesagainst one or more markers (e.g., surface antigens such as CD105, CD73,CD166, CD9, and CD157) specific for mesenchymal stem cells and analyzingthe labeled cells by flow cytometry or the like.

A larger number of the mesenchymal stem cells contained in thepharmaceutical preparation of the present invention are more preferable.However, the number of the cells is practically the minimal effectiveamount in consideration of the timing of administration to a subject andthe time required for culture. Thus, in a preferable aspect of thepharmaceutical preparation of the present invention, the number of themesenchymal stem cells is 10⁷ cells or more, preferably 5×10⁷ cells ormore, more preferably 10⁸ cells or more, even more preferably 5×10⁸cells or more.

The cell species other than mesenchymal stem cells, when intended toassist in the repair of a nervous tissue, is cells that are obtained byseparation from, for example, bone marrow, cord blood, peripheral blood,or fetal liver and are capable of differentiating into cells of thenervous system. Examples thereof can include, but not limited to,interstitial cells characterized by Lin-, Sca-1+, CD10+, CD11D+, CD44+,CD45+, CD71+, CD90+, CD105+, CDW123+, CD127+, CD164+, fibronectin+,ALPH+, and collagenase-1+, and cells characterized by AC133+.Alternatively, other arbitrary cell species capable of differentiatinginto cells of the nervous system can be used.

The interstitial cells can be obtained, for example, by selecting cellshaving a cell surface marker such as CD45, from a cell fraction obtainedby centrifugation from bone marrow cells or cord blood cells.Alternatively, these cells can also be prepared by subjecting bonemarrow cells or cord blood cells collected from vertebrates to densitygradient centrifugation at 800 g in a solution for a time sufficient forseparation according to the gravity and, after the centrifugation,collecting a cell fraction having a given gravity that falls within thegravity range of 1.07 to 1.1 g/ml. In this context, the term “timesufficient for separation according to the gravity” means a time enoughfor the cells to occupy the position, according to their gravity, in thesolution for density gradient centrifugation and is usuallyapproximately 10 to 30 minutes. The gravity of the cell fraction to becollected is preferably in the range of 1.07 to 1.08 g/ml, for example,1.077 g/ml. Examples of the solution for density gradient centrifugationthat can be used can include, but not limited to, Ficoll and Percollsolutions.

Specifically, a bone marrow fluid or cord blood collected fromvertebrates is first mixed with the same amount of a solution (PBS+2%BSA+0.6% sodium citrate+1% penicillin-streptomycin) thereas. A 5 mlaliquot thereof is mixed with a Ficoll+Paque solution (1.077 g/ml) andcentrifuged (800 g for 20 minutes) to extract a monocyte fraction. Thismonocyte fraction is mixed with a culture solution for cell washing(αMEM, 12.5% FBS, 12.5% horse serum, 0.2% i-inositol, 20 mM folic acid,0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 μM hydrocortisone, and 1%anti-biotic-antimycotic solution) and centrifuged (2000 rpm for 15minutes). Subsequently, the supernatant after centrifugation is removed,and the precipitated cells are then collected and cultured (37° C., 5%CO₂).

The AC133+cells can be obtained, for example, by selecting cells havinga cell surface marker AC133, from a cell fraction obtained bycentrifugation from bone marrow cells, cord blood cells, or peripheralblood cells. Moreover, in an alternative aspect, these cells can also beprepared by: subjecting fetal liver cells collected from vertebrates todensity gradient centrifugation at 2000 rpm in a solution for a timesufficient for separation according to the gravity; after thecentrifugation, collecting a cell fraction having a given gravity thatfalls within the gravity range of 1.07 to 1.1 g/ml; and collecting cellscharacterized by AC133+, from this cell fraction. In this context, theterm “time sufficient for separation according to the gravity” means atime enough for the cells to occupy the position, according to theirgravity, in the solution for density gradient centrifugation and isusually approximately 10 to 30 minutes. Examples of the solution fordensity gradient centrifugation that can be used can include, but notlimited to, Ficoll and Percoll solutions.

Specifically, a liver tissue collected from vertebrates is first washedin an L-15 solution, then enzymatically treated (at 37° C. for 30minutes in a solution containing L-15+0.01% DNase I, 0.25% trypsin, and0.1% collagenase), and pipetted to prepare single cells. These singlecells as fetal liver cells are centrifuged. The cells thus obtained arewashed, and from the washed cells, AC133 + cells are collected usingAC133 antibodies. As a result, the cells capable of differentiating intocells of the nervous system can be prepared from the fetal liver cells.The AC133 + cells collection using the antibodies can be performed byuse of magnet beads or a cell sorter (e.g., FACS).

The pharmaceutical preparation of the present invention is preferably aparenterally administered preparation, more preferably a parenterallysystematically administered preparation, particularly, an intravenouslyadministered preparation. Examples of dosage forms suitable forparenteral administration include, but not limited to: injections suchas soluble injections, suspensible injections, emulsifiable injections,and injections to be prepared before use; and grafts. The preparationfor parenteral administration can be in the form of aqueous ornon-aqueous isotonic sterile solutions or suspensions. Specifically, thepreparation can be prepared in an appropriate unit dosage form byappropriately combining, for example, pharmacologically acceptablecarriers or vehicles, specifically, sterilized water or saline, media,buffered saline such as PBS, plant oils, emulsifying agents, suspendingagents, surfactants, stabilizers, excipients, vehicles, preservatives,binders, and the like.

Examples of injectable aqueous solutions include, but not limited to,saline, media, buffered saline such as PBS, tonicity agents containingglucose or other adjuvants, for example, D-sorbitol, D-mannose,D-mannitol, and sodium chloride. These solutions may be used incombination with an appropriate solubilizer, for example, alcohol,specifically, ethanol or polyalcohol (e.g., propylene glycol,polyethylene glycol) and/or with a nonionic surfactant, for example,polysorbate 80 or HCO-50.

In the present invention, the injury means that a living subject suffersfrom some systemic or local damage caused by endogenous and/or foreignfactors. Thus, the injury according to the present invention encompassesvarious states such as various traumas, infarctions, degenerativelesions, and tissue destructions. Moreover, the injury site alsoencompasses various tissues in the whole body, for example, brain,nerve, kidney, pancreas, liver, heart, skin, bone, and cartilage. Theinjury site may appear at one position or may appear at a plurality ofpositions. The pharmaceutical preparation of the present invention haseffects on various tissues and can simultaneously repair a plurality ofinjury sites by one administration. Therefore, the pharmaceuticalpreparation of the present invention is particularly effective for thetreatment of a subject having a plurality of injury sites. Examples offactors that cause the injury include, but not limited to: externalphysical forces such as accidents, burns, and bombing; various ischemicdiseases such as ischemic neurological disease (cerebral infarction,spinal cord infarction, etc.) and ischemic heart disease (e.g.,myocardial infarction); various inflammations, diabetic mellitus,various infections, autoimmune diseases, tumors, exposure to poisons,central and peripheral demyelinating diseases, central and peripheraldegenerative diseases, cerebral hemorrhage, subarachnoid hemorrhage,brain tumor, higher dysfunction including dementia, psychiatricdiseases, epilepsy, and prion diseases (e.g., Creutzfeldt-Jacob disease,kuru disease, bovine spongiform encephalopathy, and scrapie). The injuryaccording to the present invention typically refers to those involvingloss and/or reduction of tissue functions.

Examples of the loss and/or reduction of tissue functions can include,but not limited to: for nervous tissues, sensory disorders (e.g., pain,numbness, and hypesthesia), motor disorders (e.g., paralysis, cramp,hemiplegia, shaky limbs, difficulty in walking, bradykinesia, andphysical awkwardness), brain dysfunction (e.g., headache, memorydisorder, disturbed consciousness, speech disorder, convulsion, tremor,dementia, hallucination, and abnormal behavior), and dysautonomia (e.g.,lightheadedness, vertigo, syncope, dysuria, and dyshidrosis); for thekidney, loss and/or reduction of excretory functions, regulatoryfunctions for bodily fluid balance such as electrolyte/water balance,and endocrine functions; for the pancreas, loss and/or reduction ofexocrine functions and endocrine functions; for the liver, loss and/orreduction of metabolic functions, synthetic functions, and exocrinefunctions; and for the heart, loss and/or reduction of blood outputfunctions and endocrine functions. Loss and/or reduction of specificfunctions caused by damage in a certain tissue as well as symptomsassociated therewith are known by those skilled in the art.

Moreover, repair and regeneration of the injury site are synonymous withrepair and regeneration of the functions. The therapeutic effects of,for example, repair/regeneration of a tissue of the nervous systemencompass neuroprotective effects (e.g., remyelination of axons),neurotrophic effects (e.g., replenishment of neuroglia cells), brainangiogenesis, nerve regeneration, and so on. Specifically, thetherapeutic effects of the pharmaceutical preparation of the presentinvention mean tissue repair/regeneration as entities andrepair/regeneration of dysfunction of the tissue as phenomena. Thetherapeutic effects on, for example, brain injury, appear as reductionof edema, remyelination of axons, increase in the number of neurogliacells, angiogenesis, nerve regeneration, and so on as entities andappear as recovery in brain blood flow, recovery from paralysis,alleviation of pain or numbness, and so on as phenomena. These effectscan be confirmed by physical examination, for example, X-rayexamination, CT scan, MRI examination, ultrasonic examination,endoscopic examination, or biopsy, on the injured tissue. In addition,the effects can also be confirmed by various hematological examinations,biochemical examinations, endocrinological examinations, motor functionexaminations, brain function examinations, cognitive functionexaminations, or the like.

The phrase the pharmaceutical preparation of the present invention“assists in the repair” of the injury site typically means, but notlimited to, that by administration of the pharmaceutical preparation ofthe present invention, the components in the present preparation help orsupport the repair mechanism of the living subject andpromote/potentiate the repair of the injury site, as compared to theabsence of administration of the present preparation. This phrase alsoencompasses prevention of injury in the injury site from being expandedor becoming more severe, blocking of injury in progress, and recoverytherefrom. The administration of the present preparation builds, at theinjury site, an environment suitable for the functions of the repairmechanism of the living subject. Specifically, the assistance in therepair brought about by the pharmaceutical preparation of the presentinvention can be brought about by, for example, but not limited to,cytokine secretion, angiogenesis, and/or tissue regeneration (see FIG.9).

Moreover, the pharmaceutical preparation of the present invention canbring about, for example: for injured kidney involving renal failure,improvement in renal function index such as BUN and/or creatininevalues; for injured pancreas involving reduction of insulin secretionfunctions of the islet of Langerhans, improvement in insulin secretionor in index for diabetic mellitus such as blood-sugar level, serum GluA1 concentration and/or serum HbA1C concentration; for injured heartattributed to ischemic heart disease, improvement in serum prostaglandinD synthase concentration and/or serum homocysteine concentration; andfor injured liver involving liver failure, improvement in index forliver function such as GOT, GPT, and/or γ-GTP values.

In a preferable aspect of the pharmaceutical preparation of the presentinvention, the pharmaceutical preparation is administered aftertreatment of the injury site. In this context, the treatment of theinjury site typically means the treatment of the injury in thehyperacute or acute phase and encompasses, for example, treatment toprevent injury from being expanded and surgical treatment to repairinjury. Moreover, in another preferable aspect, the pharmaceuticalpreparation of the present invention is administered for the purpose ofassisting in autonomous repair powder possessed by the living subject.

Moreover, the pharmaceutical preparation of the present invention ispreferably administered in the subacute phase or later of injury. Thesubacute phase refers to convalescence subsequent to the exacerbationphase (hyperacute or acute phase) of symptoms caused by the injury andrefers to a period from 1 to 2 months after the development of, forexample, cerebral infarction.

The mesenchymal stem cells in the pharmaceutical preparation of thepresent invention are preferably autologous mesenchymal stem cellsderived from cells collected from a subject having the injury site. Theuse of the autologous cells can avoid rejection or infection risk.Moreover, the autologous mesenchymal stem cells may be collected beforethe onset of injury or after the onset of injury. When the cells arecollected before the onset of injury, the collected cells must be storedby an approach such as cryopreservation after arbitrary slowdown ofgrowth or growth. This is because the onset of injury is usuallydifficult to predict. When the cells are collected after the onset ofinjury, the collected cells can be administered directly to a subjectafter arbitrary slowdown of growth or growth or can be stored thereafterby an approach such as cryopreservation (e.g., in a deep freezer at−152° C.) and appropriately administered at a chosen timing.Alternatively, all the cells can be administered simultaneously, or someof them may be stored and additionally administered, if necessary.

In the present invention, the term “subject” means an arbitrary organismindividual and is preferably an animal, more preferably a mammal, morepreferably a human individual. In the present invention, the subjecttypically has some injury site.

The present invention can be used in an evaluation method for evaluatingwhether or not cells cultured ex vivo are cells available for use inbiological tissue repair and regeneration. In one embodiment, theevaluation method according to the present invention comprises the stepof measuring an expression level of a particular gene in the cells to beevaluated. In one embodiment, the evaluation method according to thepresent invention can comprise the step of measuring an expression levelof at least one of genes described in Tables 1 to 4 in the cells to beevaluated. The evaluation method according to the present embodiment mayfurther comprise the step of comparing the expression level of at leastone of genes described in Tables 1 to 4 with that in control cells.

In the present invention, cells that are prepared from the same sourceas that of the cells to be evaluated and cultured using foreign serumare used as the control cells. The expression level of the intended genein the control cells may be measured simultaneously with measurement ofthat in the cells to be evaluated or may be measured in advance.Specifically, the evaluation method according to the present inventionmay further comprise the step of measuring the expression level of theintended gene in the control cells.

By applying the present invention to a gene described in the box B ofTables 2 to 4 as the intended gene, the cells to be evaluated aredetermined to be cells available for use in biological tissue repair andregeneration when the expression level of the intended gene in thesecells is lower than that in the control cells. Alternatively, byapplying the present invention to a gene described in the box A ofTables 2 to 4 as the intended gene, the cells to be evaluated aredetermined to be cells available for use in biological tissue repair andregeneration when the expression level of the intended gene in thesecells is higher than that in the control cells.

In the present invention, the measurement of the gene expression levelmay be performed based on an mRNA level or based on a protein level. Asdescribed above, the “gene described in the table” is intended to mean agene identified by “Probe Set ID” described in this table (this geneincludes variants that retain the functions of the gene). This is easilyunderstood by those skilled in the art based on “Gene Title” in thetable. Thus, those skilled in the art can easily construct sequencetools (e.g., primers or probes) necessary for mRNA level measurement andcan easily obtain antibodies necessary for protein level measurement.Moreover, the evaluation method according to the present invention maybe performed based on the index that the ratio of the gene expressionlevel between baseline and experiment arrays is 4 times or more in asystem described in the present Examples.

The evaluation method according to the present invention may comprisethe step of comparing the growth rate of the cells to be evaluated inthe presence of allogeneic serum with that in the presence of foreignserum. The present invention is preferably applicable to human-derivedcells. In this case, the foreign serum is preferably FBS. Human serumhas previously been known to be significantly inferior in growth-promoting activity to FBS and to exhibit insufficient cellgrowth-promoting activity by itself. Thus, it has been unexpected thatwhether or not cells are available for use in biological tissue repairand regeneration can be evaluated by comparing a cell growth rateobtained using human serum (particularly, autoserum) with that obtainedusing FBS.

EXAMPLES

Examples below are given to more specifically describe cell growthaccording to a method of the present invention and a pharmaceuticalpreparation for tissue repair/regeneration comprising the cells grown bythe method of the present invention and are not intended to limit thescope of the present invention by any means. Those having ordinaryknowledge and skills in the field of cell culture and/or cell therapycan make various modifications therein without departing from the spiritof the present invention.

Example 1

60 mL of a bone marrow fluid was collected from a brain disease patientusing a blood collection tube whose inner wall was wetted in advancewith trace heparin (0.1 U per mL of bone marrow fluid). The collectedbone marrow fluid was added to 210 mL of a medium to bring the wholeamount to 270 mL. This bone marrow fluid-containing culture solution wasdivided to 18 portions, each of which was then seeded in an amount of 15mL to a dish of 150 mm in diameter (Tissue culture dish #3030-150manufactured by IWAKI). 5 mL of the medium was added thereto to bringthe whole amount to 20 mL per dish. After the seeding, these dishes areleft standing in separate incubators (9 dishes per incubator), followedby culture at 37±0.5° C., in a 5% CO₂ atmosphere. The bone marrow fluidwas confirmed in advance by peripheral blood examination to be notinfected with HIV, ATL, HB, HC, syphilis, human parvovirus B19, and thelike.

The medium was prepared by adding 56.8 mL of serum derived fromautologous peripheral blood, 5.7 mL of an antibiotic (consisting of10,000 U/mL penicillin and 10 mg/mL streptomycin), and 5.7 mL ofglutamine (292.3 mg/L) to 500 mL of a Dulbecco's modified eagle'smedium, then sterilized by filtration, and divided to small portions,which were then stored in a cool box at 4° C. The medium was kept at 37°C. in advance and then used.

On day 4, mesenchymal stem cells adhering to the culture container werewashed. For this purpose, the medium and blood cell components floatingin the medium were separated and removed by suction, and the surface ofthe adherent mesenchymal stem cells was subsequently washed six timeswith 5 mL of phosphate-buffered saline as a wash.

On day 8, first subculture was performed. For this purpose, 4 mL of aseparation solution (0.25% trypsin-2.21 mM EDTA) for dissociating theadherent stem cells thus washed with 5 mL of phosphate-buffered salinewas added to the dish and incubated at 37° C. for 3 minutes to confirmthe dissociation. To the separation solution containing the cellsseparated from the dish, the same amount of the medium thereas wasadded, and the whole amount of the solution was collected bydecantation. The cells corresponding to the 9 dishes were respectivelytransferred to 9 centrifuge tubes and centrifuged at 800 rpm for 5minutes in a centrifuge. After the centrifugation, the supernatant ofeach centrifuge tube was removed, and the cells were collected by theaddition of DMEM. The collected cell solution was centrifuged again at800 rpm for 5 minutes. After the centrifugation, the supernatant of eachcentrifuge tube was removed, and the cells were collected by theaddition of 300 mL of the medium. This cell solution was divided tosmall portions corresponding to 15 dishes and incubated for subcultureat 37±0.5° C. at a CO₂ concentration of 5%, as in the primary culture.The same subculture procedures as above were performed for the remaining9 dishes.

On day 13, washing, dissociation, and centrifugation were performed inthe same way as above. The number of cells in each small portion wasmeasured using a hemocytometer and consequently determined to reach1.1×10⁶ cells, and thus the cells were further subcultured. The culturewas continued, and on day 20, the number of cells was measured in thesame way as above and consequently determined to reach 1.0×10⁸ cells interms of the total number. Therefore, washing, dissociation, andcentrifugation were performed, and the cells were suspended in acryopreservation solution (20.5 mL of usual RPMI sterilized byfiltration, 20.5 mL of autoserum collected from the patient, 5 mL ofdextran, and 5 mL of DMSO) and frozen at −150° C. The ratio of themesenchymal stem cells to the cells was 98% or more (CD105 positive(positive rate=99.9%), CD34 negative (negative rate=98.8%), and CD45negative (negative rate=98.5%).

Comparative Example 1

Culture was performed under the same conditions as in Example 1 exceptthat the content of heparin in the sample was changed to 2 mL (267U/mL). The results are shown in FIGS. 1 and 2. When heparin was addedonly in a trace amount (0.1 U/mL), growth to 8×10⁵ cells was obtainedafter 4 days into culture. By contrast, when 2 mL of heparin was added,growth to 2×10⁴ cells was obtained. Thus, the growth rate obtained usingtrace heparin was about 40 times higher (FIGS. 1 and 2). In thecontinued culture, the number of cells was increased after 12 days intoculture to 1.4×10⁷ cells by the addition of trace heparin and, bycontrast, to 2.9×10⁶ cells by the addition of 2 mL of heparin (FIG. 1).These results show that the addition of heparin has inhibitory effectson cell growth and also demonstrate that the method of the presentinvention can rapidly grow cells even when an anticoagulant is added ina trace amount or is substantially absent. These results further showthat the growth rate is significantly improved by setting the amount ofheparin in a sample to a trace amount.

Comparative Example 2

Culture was performed for 8 days under the same conditions as in Example1 except that FBS was used instead of serum derived from humanperipheral blood. Comparison in the growth rate of mesenchymal stemcells based on the measurement of the number of cells is shown in FIG.3. When human mesenchymal stem cells were cultured under the conditionsof the present invention, the use of human adult serum produced growthrates about 2.6 times higher after 5 days into culture and about 6 timeshigher after 8 days thereinto than those obtained using FBS. Theseresults show that in the culture of human bone marrow cells, the use ofhuman adult serum produces a higher growth rate than that of obtainedusing FBS, by setting the amount of heparin in a sample to a traceamount.

Comparative Example 3

An experiment was conducted using rat mesenchymal stem cells. Bonemarrow cells collected from two rat thigh bones were cultured in thesame medium as in Example 1 supplemented with 1 U/mL, 10 U/mL, 100 U, or1000 U/mL heparin. Culture was performed under the same conditions as inExample 1 except that FBS was used instead of serum derived from humanperipheral blood. The results are shown in FIG. 4. These results showedthat a higher concentration of heparin in a medium has higher inhibitoryeffects on growth.

Comparative Example 4

An experiment was conducted as follows using rat mesenchymal cells: fora first group, a bone marrow fluid was forced out of one rat thigh boneusing 4 mL of DMEM to prepare a little over 4 mL in total of a sample.This sample was added to 36 mL of DMEM supplemented with 160 U ofheparin, and culture was started. The concentration of heparin in themedium was 4 U/mL. For a second group, a bone marrow fluid was forcedout of one rat thigh bone using 4 mL of DMEM supplemented with 160 U ofheparin to prepare a little over 4 mL in total of a sample. This samplewas left at room temperature for 5 minutes in this state where it wasexposed to the high concentration of heparin. Then, 36 mL of DMEM wasadded thereto, and culture was started. The concentration of heparin inthe medium was 4 U/mL. Changes in the number of cells for these twogroups are shown in FIG. 5. The second group was observed to have a muchlower growth rate than that of the first group. These results suggestthat the addition of heparin to a cell sample during sample collection(or before shift to culture) produces lower cell growth efficiency thanthat obtained by the addition of heparin to a medium at the time ofculture.

Example 2

Culture was performed under the same conditions as in Example 1 exceptthat an αMEM medium was used instead of DMEM as a standard medium. Theresults are shown in FIG. 6. These results demonstrated that when anαMEM medium was used, the use of human serum produces more rapid growththan obtained with FBS, by reducing the amount of heparin as well.

Comparative Example 5

Culture was performed for 7 days in the same way as in Example 1 exceptthat the medium was free from glutamine. Comparison in the growth rateof mesenchymal stem cells based on the measurement of the number ofcells is shown in FIG. 7. The use of glutamine produced a growth rateabout 1.6 times higher after 1 week into culture than that obtained inthe absence of glutamine. These results show that the addition ofglutamine is required for the rapid growth of mesenchymal stem cells.

Example 3 Method

Three rat thigh bones were collected, and bone marrow cells were washedout of each thigh bone using DMEM (5 ml) and supplemented with thefollowing agents to prepare three sample groups:

(i) DMEM (5 ml)

(ii) DMEM (5 ml)+heparin (2 μl)(iii) DMEM (5 ml)+heparin (2 μl)+protamine (2 μl)

Each sample was washed with DMEM and placed in 10 ml of a culturesolution (DMEM+10% FBS+1% penicillin/streptomycin+2 mM L-glutamine),which was then seeded to a 10 cm dish and cultured for 14 days.Subculture was started at the point in time when the cell densityexceeded 5,500 cells/cm².

Results

As shown in FIG. 8, the cells untreated with heparin had a largerinitial amount and also a higher growth rate than those of the cellstreated with heparin, and this was obvious on culture days 8 to 11.Moreover, the cells supplemented with protamine, a substance inhibitingheparin activity, also had a low initial amount and a low growth rate,as in the cells treated with heparin.

Example 4

Under conditions where cells were cultured without substantial contactwith heparin, i.e., under conditions involving a low heparinconcentration, autoserum-cultured mesenchymal stem cells were comparedwith FBS-cultured mesenchymal stem cells.

cDNA Synthesis and Purification

Mesenchymal stem cells cultured in an autoserum-containing mediumaccording to the method of Example 1 and mesenchymal stem cells culturedin an FBS-containing medium according to the method of ComparativeExample 2 were separately adjusted to 1×10⁷ cells/sample. From eachsample, total RNA was extracted using RNeasy Protect Min Kit (QIAGEN,Cat. No. 74124). For cell disruption, QIA shredder (QIAGEN, Cat. No.79654) was used. The obtained RNA solution was adjusted to 0.5 μg/μl,and the quality of RNA was checked using Agilent 2100 Bioanalyzer(Agilent Technologies, Inc.).

1^(st) strand cDNA was synthesized using GeneChip Eukaryotic Poly-A RNAControl Kit (AFFYMETRIX, Inc., P/N900433) and MessageAmp II-BiotinEnhanced Kit (Ambion, Inc., Catalog #1791). Specifically, a reactionsolution (II) was added to a reaction solution (I) reacted at 70° C. for10 minutes, and 20 μl in total of the reaction system was reacted at 42°C. for 2 hours.

[Formula 1] Reaction solution (I) Total RNA (0.5 μg/μl) 2 μl Dilutedpoly-A RNA controls 2 μl T7-Oligo(dT) Primer, 50 μM 1 μl RNase-freewater 7 μl Total 12 μl 

[Formula 2] Reaction solution (II) 10 × First Strand Buffer 2 μl dNTPMix 4 μl Rnase Inhibitor 1 μl ArrayScript 1 μl Total 8 μl

Subsequently, 2^(nd) strand cDNA was synthesized and purified usingMessageAmp II-Biotin Enhanced Kit (Ambion, Inc., Catalog #1791).Specifically, a reaction solution (III) was added to the reactionsolution (II) thus reacted, and 100 μl in total of the reaction systemwas reacted at 16° C. for 2 hours. For cDNA purification, cDNA FilterCartridge included in the kit was used, and finally 24 μl ofNuclease-free Water was added in two portions to the Filter for elution.

[Formula 3] Reaction solution (III) Nuclease-free Water 63 μl 10 ×Second Strand Buffer 10 μl dNTP Mix  4 μl DNA Polymerase  2 μl RNase H 1 μl Total 80 μl

IVT reaction and aRNA purification were performed using MessageAmpII-Biotin Enhanced Kit (Ambion, Inc., Catalog #1791). Specifically, areaction solution (IV) was reacted at 37° C. for 14 hours. Then, thereaction was terminated by the addition of 60 μl of Nuclease-free Water.For aRNA purification, aRNA Filter Cartridge included in the kit wasused, and finally 100 μl of Nuclease-free Water was added to the Filterfor elution. The obtained RNA solution was adjusted to 20 μg/32 μl, andthe quality of RNA was checked using Agilent 2100 Bioanalyzer (AgilentTechnologies, Inc.)

[Formula 4] (Reaction solution IV) Double-stranded cDNA 20 μl Biotin-NTPMix 12 μl T7 10 × Reaction Buffer  4 μl T7 Enzyme Mix  4 μl Total 40 μl

Preparation of Hybridization Cocktail

The aRNA was fragmented using MessageAmp II-Biotin Enhanced Kit (Ambion,Inc., Catalog #1791) to prepare Hybridization Cocktail. Specifically, areaction solution (V) was reacted at 94° C. for 35 minutes. Then,Hybridization Cocktail was prepared using GeneChip Expression3′-Amplification Reagents Hybridization control kit (AFFYMETRIX, Inc.,P/N900454) and reacted at 99° C. for 5 minutes and then at 45° C. for 5minutes.

[Formula 5] (Reaction solution V) aRNA(20 μg/32 μl) 32 μl 5 × ArrayFragmentation Buffer  8 μl Total 40 μl

[Formula 6] (Hybridization Cocktail) Fragmented cRNA 30 μl ControlOligonucleotide B2  5 μl 20 × Eukaryotic hybridization Controls 15 μlHerring Sperm DNA(10 mg/ml)  3 μl BSA(50 mg/ml)  3 μl 2 × HybridizationBuffer* 150 μl  DMSO 30 μl H₂O 64 μl Total 300 μl  *Hybridization Buffer(1 × conc.; 100 mM MES, 0.1M [Na⁺], 20 mM EDTA, 0.01% Tween-20)

Hybridization

GeneChip Human Genome U133 Plus 2.0 Array (AFFYMETRIX, Inc., P/N900466)was filled with 1×Hybridization buffer, followed by prehybridization at60 rpm at 45° C. for 10 minutes. Then, the 1×Hybridization buffer wasremoved, and the array was filled with the prepared HybridizationCocktail, followed by overnight hybridization at 60 rpm at 45° C.

Washing and Staining

Wash Buffer A (6×SSPE, 0.01% Tween-20), Wash Buffer B (100 mM MES, 0.1 M[Na+], 0.05% Tween-20), and water were loaded in Fluidics Station, andpriming was performed according to the program of GCOS (GeneChipOperating Software). Subsequently, the Hybridization Cocktail wasremoved, and the array was filled with Wash Buffer A. This array, SAPESolution Mix (1×Stain buffer, 2 mg/ml BSA, 10 μg/ml SAPE), and AntibodySolution Mix (1×Stain buffer, 2 mg/ml BSA, 0.1 mg/ml Goat IgG Stock, 3μg/ml biotinylated antibody) were loaded in the Fluidics Station. Then,washing and staining were performed according to the program of GCOS.

Scan

Gene Array Scanner was loaded in the array, and scan and analysis wereperformed. The analysis results are shown in Tables 1 to 5.

TABLE 1 Expression of cell surface antigens (CD antigens) PositiveNegative CD9 CD1 CD72 CD29 CD4 CD74 CD44 CD5 CD79 CD47 CD6 CD84 CD58 CD7CD86 CD59 CD8 CD93 CD63 CD14 CD96 CD73 CD19 CD117 CD81 CD22 CD133 CD97CD24 CD163 CD99 CD28 CD177 CD105 CD33 CD180 CD109 CD34 CD207 CD151 CD37CD209 CD157 CD38 CD226 CD164 CD45 CD244 CD166 CD48 CD247 CD200 CD53CD274 CD248 CD68 CD300 CD69

TABLE 2 Expression of growth factor-related factors Gene Title GeneSymbol A. Gene group with increased expression (FBS⇒autoserum)synaptotagmin-like 4 (granuphilin-a) SYTL4 regulator of G-proteinsignalling 10 RGS10 regulator of G-protein signalling 2, 24 kDa RGS2 B.Gene group with decreased expression (FBS⇒autoserum) peroxisomeproliferator-activated receptor delta PPARD protocadherin beta 14PCDHB14 protocadherin beta 2 PCDHB2 junctional adhesion molecule 3 JAM3junctional adhesion molecule 3 JAM3 Ras association (RalGDS/AF-6) domainfamily 8 RASSF8 PPAR binding protein PPARBP protocadherin beta 10PCDHB10 ribonucleotide reductase M2 B (TP53 inducible) RRM2B plateletderived growth factor D PDGFD RAS protein activator like 2 RASAL2 PERP,TP53 apoptosis effector PERP dickkopf homolog 3 (Xenopus laevis) DKK3junctional adhesion molecule 3 JAM3 flightless 1 homolog (Drosophila)FLI1 synaptotagmin XI SYT11 inhibitor of DNA binding 3, dominantnegative ID3 helix-loop-helix protein transforming growth factor, betareceptor 1 (activin A TGFBR1 receptor type II-like kinase, 53 kDa)cadherin 6, type 2, K-cadherin (fetal kidney) CDH6 Wilms tumor 1associated protein WTAP MYC binding protein 2 MYCBP2 activated leukocytecell adhesion molecule ALCAM activated leukocyte cell adhesion moleculeALCAM lumican LUM inhibitor of DNA binding 2, dominant negative ID2 ///ID2B helix-loop-helix protein /// inhibitor of DNA binding 2B, dominantnegative helix-loop-helix protein inhibitor of DNA binding 2, dominantnegative ID2 helix-loop-helix protein MYC binding protein 2 MYCBP2catenin (cadherin-associated protein), beta 1, 88 kDa CTNNB1

TABLE 3 Expression of related cytokines Gene Title Gene Symbol A. Genegroup with increased expression (FBS⇒autoserum) insulin-like growthfactor 2 mRNA binding protein 2 IGF2BP2 hepatoma-derived growth factor,related protein 3 HDGFRP3 hepatoma-derived growth factor, relatedprotein 3 HDGFRP3 epidermal growth factor (beta-urogastrone) EGF B. Genegroup with decreased expression (FBS⇒autoserum) heparin-binding EGF-likegrowth factor HBEGF meteorin, glial cell differentiation regulator-like/// LOC683806 similar to meteorin, glial cell differentiation /// METRNLregulator-like stromal cell derived factor 4 SDF4 chemokine (C—X—Cmotif) receptor 7 CXCR7 insulin-like growth factor binding protein 3IGFBP3 insulin-like growth factor binding protein 5 IGFBP5 insulin-likegrowth factor binding protein 5 IGFBP5 fibroblast growth factor 7(keratinocyte growth factor) FGF7 heparin-binding EGF-like growth factorHBEGF insulin-like growth factor binding protein 5 IGFBP5 solute carrierfamily 1 (glial high affinity glutamate SLC1A3 transporter), member 3insulin-like growth factor 2 (somatomedin A) IGF2 insulin-like growthfactor binding protein 4 IGFBP4 fibroblast growth factor 7 (keratinocytegrowth factor) /// FGF7 /// keratinocyte growth factor-like protein 1/// keratinocyte KGFLP1 /// growth factor-like protein 2 KGFLP2

TABLE 4 Gene group whose expression level differed by two times or moreGene Title Gene Symbol A. Gene group with increased expression(FBS⇒autoserum) mastermind-like 3 (Drosophila) MAML3 FK506 bindingprotein 5 FKBP5 FK506 binding protein 5 FKBP5 brain expressed, X-linked1 BEX1 ADAM metallopeptidase domain 19 (meltrin beta) ADAM19 epidermalgrowth factor (beta-urogastrone) EGF fibrillin 2 (congenitalcontractural arachnodactyly) FBN2 B. Gene group with decreasedexpression (FBS⇒autoserum) Transcribed locus, strongly similar to —XP_001142613.1 hypothetical protein [Pan troglodytes] gremlin 2,cysteine knot superfamily, homolog GREM2 (Xenopus laevis) ADAMmetallopeptidase with thrombospondin ADAMTS5 type 1 motif, 5(aggrecanase-2) ADAM metallopeptidase with thrombospondin ADAMTS5 type 1motif, 5 (aggrecanase-2) fibronectin type III domain containing 1 FNDC1gremlin 2, cysteine knot superfamily, homolog GREM2 (Xenopus laevis)filaggrin FLG microfibrillar associated protein 5 MFAP5 chemokine (C—X—Cmotif) receptor 7 CXCR7 hypothetical protein DKFZP686A01247 hypotheticalprotein DKFZP686A01247 keratin 17 KRT17 phosphatidic acid phosphatasetype 2B PPAP2B insulin-like growth factor binding protein 5 IGFBP5insulin-like growth factor binding protein 5 IGFBP5 prostaglandin Esynthase PTGES phosphatidic acid phosphatase type 2B PPAP2B inhibitor ofDNA binding 3, dominant negative ID3 helix-loop-helix proteinprostaglandin E synthase PTGES SMAD family member 6 SMAD6 fibroblastgrowth factor 7 (keratinocyte growth FGF7 factor) cartilage oligomericmatrix protein COMP secretogranin II (chromogranin C) SCG2 hemeoxygenase (decycling) 1 HMOX1 insulin-like growth factor binding protein5 IGFBP5 insulin-like growth factor 2 (somatomedin A) IGF2 integrin,alpha 6 ITGA6 inhibitor of DNA binding 2, dominant negative ID2 /// ID2Bhelix-loop-helix protein /// inhibitor of DNA binding 2B, dominantnegative helix-loop-helix protein inhibitor of DNA binding 2, dominantnegative ID2 helix-loop-helix protein ADAM metallopeptidase withthrombospondin ADAMTS5 type 1 motif, 5 (aggrecanase-2)

Results

Table 1 shows cell surface antigens that exhibited an increased ordecreased level in common in 5 cases involving the FBS-cultured cellsand the autoserum-cultured cells. Table 2 shows growth factor-relatedfactors that exhibited increased or decreased expression in common inthese 5 cases. Moreover, Table 3 shows cytokines that exhibitedincreased or decreased expression in common in these 5 cases.Furthermore, Table 4 shows a gene group whose expression level differedby two times or more in common in these 5 cases.

As shown in Table 1, the differentiation marker CD24 expressed in theFBS-cultured cells was not expressed in the autoserum-cultured cells,demonstrating that the autoserum- cultured cells maintained a moreundifferentiated state. Moreover, as shown in Tables 2 to 4, a series ofgrowth factors were expressed in the autoserum-cultured cells, and somegrowth factors exhibited increased expression, as compared to the FBS-cultured cells. Furthermore, the results of the present analysisdemonstrated that autoserum-cultured cells have low expression of thegroup of a series of cancer-related genes and are thus highly safe.

It was thus confirmed that the culture method of the present inventionusing autoserum can culture cells with high growth efficiency withoutusing FBS and produces cells having higher safety and higherdifferentiation potency.

Example 5

A patient (52-year-old male) with ischemic neurological disease(cerebral infarction: right internal carotid artery occlusion) developedleft-sided paralysis on Feb. 4, 2007 and was transferred to SapporoMedical University Hospital on Feb. 19 of this year. Before treatment,the patient had symptoms: he was left-sided paralyzed and had severeparalysis particularly in the upper extremity; he could not clench andrelax his fist at all; he could not hold and release an object (buildingblock, etc.); he could not raise the arm above the level of theshoulder; and he could not flex and extend his wrist. From this patient,mesenchymal stem cells were collected and grown as described inExample 1. To the whole amount thereof, a cryopreservation solution(20.5 mL of usual RPMI sterilized by filtration, 20.5 mL of autoserumcollected from the patient, 5 mL of dextran, and 5 mL of DMSO) was addedto produce a therapeutic drug. The bone marrow fluid from the patientwas confirmed in advance by peripheral blood examination to be notinfected with HIV, ATL, HB, HC, syphilis, human parvovirus B19, and thelike. This therapeutic drug was intravenously administered to thepatient over 30 minutes on March 19. No side effect was observed.

Results

This patient had motor dysfunction in all five fingers of the left handbefore the cell therapy and however, the next morning of celladministration, became able to move the totally immovable fingers of theleft hand and to clench and relax his fist. One week later, improvementin motor function was observed, and he was able to do physical activityof carrying a stick. Two weeks later, evident reduction in cerebralinfarction size was confirmed by MRI (FIG. 10). Moreover, he became ableto clench and relax his fist faster and to hold and release a buildingblock. He also became able to raise the arm above the level of theshoulder and to have the “banzai” posture (throw his arms in the air).He also became able to flex and extend his elbow and wrist. Changes inthe cerebral infarction level of this patient during the periodcentering on the cell therapy are shown in FIG. 11 using well knownscales for cerebral infarction evaluation (NIHSS: National Institutes ofHealth Stroke Scale, JSS: Japan Stroke Scale, and MRS: Modified RankingScale).

FIG. 10 is an MRI image of the brain of this patient. Reduction in thesize of the site (white portion) injured by cerebral infarction in theright cerebrum was observed. Moreover, FIG. 12 is a brain blood flowimage of this patient, wherein recovery in brain blood flow at theinjury site was observed after 1 week of treatment. These results,together with the recovery in motor function shown above, demonstratedthat the administration of the present preparation exhibits significantimprovement effects in the subacute phase or later. These results,together with the recovery in motor function, demonstrated that theadministration of the pharmaceutical preparation of the presentinvention exhibits significant improvement effects on cerebralinfarction in the subacute phase or later.

Example 6

A patient (fiftysomething female) suffered from spontaneous occlusion ofthe circle of Willis (moyamoya disease) for a long period and therebydeveloped left-sided paralysis. From this patient mesenchymal stem cellswere collected and cultured in the same way as in Example 1. About 2months after the development, the cells were intravenously administeredto this patient. Improvement in brain blood flow was confirmed by MRI(PWI) examination conducted after administration.

Example 7

A patient (sixtysomething male) developed left-sided paralysisattributed to atherothrombosis. From this patient, mesenchymal stemcells were collected and cultured in the same way as in Example 1. Fourmonths after the development, the cells were intravenously administeredto this patient. As a result, alleviation of stiffness and the increasedrange of joint motion were observed since the next day ofadministration. In the passage afterwards, he significantly recoveredmuscle strength to achieve a measurable level of grasping power (4 kg).Furthermore, about 2.5 months after administration, he was able to walkby himself and recovered the left hand function to a practicallyavailable level.

Example 8

A patient (fiftysomething male) developed left-sided paralysisattributed to atherothrombosis. From this patient, mesenchymal stemcells were collected and cultured in the same way as in Example 1. Sixweeks after the development, the cells were intravenously administeredto this patient. As a result, finger movement was improved since thenext day of administration. In the passage afterwards, he significantlyrecovered muscle strength to achieve a measurable level of graspingpower (8 kg). Moreover, he became able to perform finer tasks morequickly and also recovered the strength of his finger tips enough to,for example, split apart a pair of chopsticks. Thus, he became able toperform activities helpful in daily life.

Example 9

A patient (sixtysomething male) developed left-sided paralysisattributed to atherothrombosis. From this patient, mesenchymal stemcells were collected and cultured in the same way as in Example 1. Fiveweeks after the development, the cells were intravenously administeredto this patient. As a result, he felt improvement mainly in the movementof the lower extremity since the night of the administration day andfelt improvement even in the movement of the hand the next day ofadministration. In the passage afterwards, improvement in motor functionwas continued.

Example 10

A patient (seventysomething male) developed left-sided paralysis andalalia attributed to lacunar infarction. From this patient, mesenchymalstem cells were collected and cultured in the same way as in Example 1.Eight weeks after the development, the cells were intravenouslyadministered to this patient. As a result, he became able to move histoes since the next morning of administration, and improvement in themovement of the shoulder and elbow was also observed. Then, 3 days afteradministration, he recovered enough to move the fingers.

Example 11

From a chronic diabetic mellitus patient, mesenchymal stem cells werecollected and cultured in the same way as in Example 1 and intravenouslyadministered to this patient. As a result, his blood-sugar level, whichwas around 190 mg/dl before administration, was improved to the normallevel in approximately 1 month after administration. In addition,evident improvement was also seen in other indexes for diabetic mellitus(FIG. 13).

Example 12

From a benign prostatic hyperplasia patient, mesenchymal stem cells werecollected and cultured in the same way as in Example 1 and intravenouslyadministered to this patient. As a result, the administration evidentlyimproved a PSA value serving as an index for benign prostatichyperplasia from that before administration (FIG. 14).

Example 13

From a liver damage patient, mesenchymal stem cells were collected andcultured in the same way as in Example 1 and intravenously administeredto this patient. As a result, the administration evidently improvedγ-GTP, GOT, and GPT values serving as indexes for liver damage fromthose before administration (FIG. 15).

Example 14

From a kidney damage patient, mesenchymal stem cells were collected andcultured in the same way as in Example 1 and intravenously administeredto this patient. As a result, the administration evidently improved aβ₂-microglobulin value serving as an index for kidney damage from thatbefore administration and also evidently improved other indexes forkidney damage (BUN and/or creatinine values) (FIG. 16).

Example 15

From a hyperlipemia patient, mesenchymal stem cells were collected andcultured in the same way as in Example 1 and intravenously administeredto this patient. As a result, the administration evidently improved aneutral fat value serving as an index for hyperlipemia from that beforeadministration and also evidently improved other indexes forhyperlipemia (FIG. 17).

Example 16

From a higher brain dysfunction/aphasia patient, mesenchymal stem cellswere collected and cultured in the same way as in Example 1 andintravenously administered to this patient. Before and afteradministration, the patient was subjected to Standard Language Test ofAphasia (SLTA) and Wechsler Adult Intelligence Scale-Revised (WAIS-R).As a result, the administration significantly improved SLTA and WAIS-Rvalues from those before administration (FIG. 18).

Example 17

From a healthy human, mesenchymal stem cells were collected and culturedin the same way as in Example 1. The human mesenchymal stem cells wereprepared for rat cerebral infarction models (middle cerebral arteryocclusion models). Subsequently, the rat models were divided into (i) auntransplanted group, (ii) a cell (1.0×10⁶)-intravenously injectedgroup, (iii) an angiopoietin gene-transfected-cell(1.0×10⁶)-intravenously injected group, (iv) a VEGFgene-transfected-cell (1.0×10⁶)-intravenously injected group, and (v) anangiopoietin/VEGF gene-transfected-cell (1.0×10⁶)-intravenously injectedgroup, and then treated, and the therapeutic effects were studied bycomparison. As a result of examining the therapeutic effects by MRI(FIG. 19A), the therapeutic effects were seen in the groups (ii), (iii),and (v) with the strength of the therapeutic effects in order of(v)>(iii)>(ii).

Moreover, as a result of analyzing the therapeutic effects from theaspects of angiogenesis (FIG. 19B), the therapeutic effects were seen inthe groups (ii), (iii), (iv), and (v) with the strength of thetherapeutic effects in order of (v)>(iii)>(iv)>(ii).

Moreover, as a result of analyzing the therapeutic effects usingTreadmill stress test from the behavioral aspects (FIG. 20), thetherapeutic effects were seen in the groups (ii), (iii), and (v) withthe strength of the therapeutic effects in order of (v)>(iii)>(ii).

Example 18

From a healthy human, mesenchymal stem cells were collected and culturedin the same way as in Example 1. The human mesenchymal stem cells(1.0×10⁶) were intravenously administered to rat cardiopulmonary arrestmodels, and the therapeutic effects were determined. The treatmentsuppressed apoptosis (reduced the number of Tunnel-positive cells) (FIG.21A), and a large number of neuron cells survived (FIG. 22). Moreover,the higher functions of the brain were evaluated according to Morriswater maze test. As a result, improvement therein was seen in thetreated group.

Example 19

From a healthy human, mesenchymal stem cells were collected and culturedin the same way as in Example 1. An NYU impactor was used for the spinalcords (Th11) of rats subjected to laminectomy to prepare spinal cordinjury models. After 6 hours, 1 day, 3 days, 7 days, or 14 days, thehuman mesenchymal stem cells (1.0×10⁶) were transplanted through thefemoral vein to the rat models, and their activities were evaluated overtime by Treadmill test. Specifically, a treadmill set in motion at aspeed of 20 m/min was designed in advance to apply electric shock torats that stopped running, and the rats were trained to run in 20-minutesession (per day) two days a week since before the creation of cerebralinfarction. The time-dependent degree of recovery was plotted for eachgroup with a time as abscissa against a maximum speed as ordinate.Marked therapeutic effects were seen in the groups that receivedtransplantation after 6 hours or 1 day of the creation of spinal cordinjury (FIG. 23).

All publications, patents, and patent applications cited herein areincorporated herein by reference in their entirety.

INDUSTRIAL APPLICABILITY

The present invention achieves rapid provision of a therapeutic drugthat exhibits significant effects on tissue repair/regeneration. Thisrapid provision of the therapeutic drug has great effects particularlyon disease for which early cell therapy is effective, for example, oncerebral nerve regeneration for a patient having an injured cerebralnerve. Furthermore, it relieves the shortage of cell donors and reducestheir physical burden. A pharmaceutical preparation produced by themethod of the present invention has effects as a therapeutic drug, ofcourse. In addition, the pharmaceutical preparation significantlyimproves the QOL of patients owing to the therapeutic effectspotentiated by the rapid provision and also reduces the burden ofcaregivers and the cost of care, leading to reduction in social burden.Thus, the present invention sheds light on the aging society.

What is claimed is:
 1. A method for tissue repair/regenerationcomprising administering to a subject in need thereof an effectiveamount of mesenchymal stem cells, wherein the mesenchymal stem cellswere collected from bone marrow or blood without contact with ananticoagulant-effective amount of an anticoagulant, and culturing thecollected mesenchymal stem cells in a medium comprising allogenic orautogenic serum, wherein the amount of any anticoagulant in the mediumis less than an amount which is effective for anticoagulation duringcollection of the cells.
 2. The method according to claim 1, wherein thecells are free from CD24 expression.
 3. The method according to claim 1,wherein the medium has a serum content of 1 to 20% by volume.
 4. Themethod according to claim 1, wherein the cells are human cells.
 5. Themethod according to claim 1, wherein the cells are derived from thesubject being treated.
 6. The method according to claim 1, wherein thecells are administered intravenously, via lumbar puncture,intracerebrally, intracerebroventricularly, locally, or intraarterially.7. The method according to claim 1, wherein the cells are administeredin the subacute phase or later of disease or disorder, wherein thedisease or disorder is any selected from kidney damage, liver damage,pancreatic disorder, benign prostatic hyperplasia, hyperlipemia, higherbrain dysfunction, post-resuscitation encephalopathy, heart disease, andspinal cord injury.
 8. The method according to claim 1, wherein themethod assists in the repair of an injury site by cytokine secretion,angiogenesis, and/or nerve regeneration.
 9. The method according toclaim 8, wherein the injury site is kidney.
 10. The method according toclaim 9, wherein the assistance in the repair involves improvement inBUN value and/or creatinine value and/or β₂ microglobulin value.
 11. Themethod according to claim 8, wherein the injury site is pancreas. 12.The method according to claim 11, wherein the assistance in the repairinvolves improvement in blood-sugar level, serum Glu A1 concentration,and/or serum HbA1C concentration.
 13. The method according to claim 8,wherein the injury site is heart.
 14. The method according to claim 13,wherein the assistance in the repair involves improvement in serumprostaglandin D synthase concentration and/or serum homocysteineconcentration.
 15. The method according to claim 8, wherein the injurysite is liver.
 16. The method according to claim 14, wherein theassistance in the repair involves improvement in GOT value, GPT value,and/or yγ-GTP value.
 17. The method according to claim 8, wherein theinjury site is brain.
 18. The method according to claim 17, wherein theassistance in the repair involves improvement in SLTA value and/orWAIS-R value.
 19. The method according to claim 8, wherein the injurysite is prostate.
 20. The method according to claim 19, wherein theassistance in the repair involves improvement in PSA value.